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Abstract Title: Characterization of the influences of Human Cytomegalovirus glycoprotein O (gO)
expression on gH/gL complexes assembly and its polymorphisms on cell-free and cell-to-cell spread,
and antibody neutralization.
Research Advisor: Dr. Brent J. Ryckman

Human cytomegalovirus (HCMV) is widely spread throughout the world and
immunocompromised individuals can suffer severe diseases from HCMV infection. Once the
infection is established, HCMV can spread through the body and infect many major somatic
cell types. The glycoproteins H and L (gH/gL) on HCMV envelope can be bound by either gO
or the UL128-131 proteins to form complexes gH/gL/gO and gH/gL/UL128-131 that are
critical for viral entry and spread, and these two complexes are important targets of
neutralizing antibodies. Strains of HCMV vary considerably in the levels of gH/gL/gO and
gH/gL/UL128-131. gO is one of the most diverse loci among strains with 10-30% of amino
acid sequence differences. In this thesis I explored the mechanisms behind the complex
assembly differences between strains and the impacts of interstrain gO diversity on the
biology of HCMV. My results uncovered that the strain variations in the assembly of gH/gL
complexes is due to the differences in the expression level of gO and UL128-131, while gO
amino acid sequence differences have no influence on the complexes assembly.
Interestingly, the diversity of gO has dramatic impacts on HCMV cell-free and cell-to-cell
spread as well as on antibody neutralization and these effects of gO polymorphisms are
epistatically dependent on other variable loci in the virus genome. My study could help to
understand the complexity of genotypes observed in clinical samples and decode the
challenge for intervention approaches against HCMV.
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Chapter I. Introduction

1

Overview of Human Herpesviruses
a. Herpesviridae
Herpesviridae is a large family of DNA viruses and the members of this family are
also known as herpesviruses. There are more than 130 herpesviruses in total and
they are found in mammals, fish, reptiles, birds, and mollusks. Based on biological
and genetic properties, the herpesviruses are divided into three subfamilies:
alphaherpesvirinae, betaherpesvirinae, and gammaherpesvirinae [1]. In hosts, the
life cycle of herpesviruses can be divided into lytic and latent infections. The lytic
infection leads to production of progenies, while the viral replication is suppressed
during latent infection. The establishment of latency is a unique characteristic of
herpesviruses.

b. Human Herpesviruses
There are eight herpesviruses that are known to utilize human as primary host:
herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella-zoster
virus (VZV), Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), human
herpesvirus-6 (HHV-6), human herpesvirus-7 (HHV-7), and Kaposi’s sarcoma
herpes virus (KSHV).

HSV-1, HSV-2, and VZV belong to the alpha subfamily and they have the
characteristics of short replication cycle in the host, rapid growth, and the
establishment of latency in sensory ganglia [1]. The beta human herpesviruses,
including HCMV, HHV-6, and HHV-7, have relative long replication cycle in the host
2

compared to alpha human herpesviruses. The latency of beta herpesviruses are
established in lymphocytes, secretory glands, and other cell types [4]. EBV and
KSHV, the gamma herpesviruses, have limited host cell tropism compared to
alphaherpesvirinae and betaherpesvirinae. They develop long-term latency in Bcells/ memory B-cells and replicate in epithelial cells [Table 1.1].

Table 1.1. Major properties of human herpesviruses

Name

Formal name

Type

Primary target cells

Main sites of latency

Herpes simplex
virus-1 (HSV-1)

Human
herpesvirus 1

Alpha

Mucoepithelia

Sensory and
cranial nerve ganglia

Herpes simplex
virus-2 (HSV-2)

Human
herpesvirus 2

Alpha

Mucoepithelia

Sensory and
cranial nerve ganglia

Varicella zoster
virus (VZV)

Human
herpesvirus 3

Alpha

Mucoepithelia

Sensory and
cranial nerve ganglia

Epstein-Barr
virus (EBV)

Human
herpesvirus 4

Gamma

Epithelial and
B-cell

Human
Cytomegalovirus
(HCMV)

Human
herpesvirus 5

Beta

Roseola virus
(HHV-6)

Human
herpesvirus 6

Beta

T-cells

Rosela virus
(HHV-7)

Human
herpesvirus 7

Beta

T-cells

Kaposi’s sarcomaassociated virus
(KSHV)

Human
herpesvirus 8

Gamma

lymphocytes
and epithelia

Monocytes,
lymphocytes, epithelial,
fibroblasts…
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Memory B-cells

Monocytes,
lymphocytes

Various
leukocytes
T-cells, epithelia

B-cells

Overview of Human Cytomegalovirus
a. HCMV structure
The virion of HCMV is approximately 230nm in diameter and consists four major
components: the core, capsid, tegument, and envelope [2](Fig 1.1). The core
contains a linear double-stranded viral DNA genome, which is located inside an
icosahedral-shaped capsid. Between the capsid and lipid envelope, there is a layer of
tegument proteins, which are responsible for connecting the capsid to the envelope
and storing viral proteins that are essential for initiation of infection. The outermost
layer is viral lipid bilayer envelope and it contains viral glycoproteins that facilitate
virus attachment, signaling transduction, and fusion into the host cell.

Fig 1.1. Virion particle in cytoplasm of HCMV-infected cell. (Modified from [2])

1. Genome
HCMV has the largest genome among human herpesviruses. The whole genome size
is about 235kb, which is over 50% larger than that of herpes simplex virus type
1(HSV-1). According to the herpesviruses genome structure classification [5], HCMV
genome has class E repeated region organization and it is the most complex genome
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structure among human herpesviruses. The two major domains are known as the
long and short genome segments (L and S) and each includes a unique region (UL
and US) at the center. The unique regions are flanked by repeated sequences at both
the two ends of the genome (TRL and TRS) and the intersection between the long
and short segments (IRL and IRS). Besides, there are few hundred base pair repeated
at the two ends of the viral genome and the IRL-IRS junction, which is termed as a
sequence [6]. Consequently, HCMV genome has the structure organization of: a-TRLUL-IRL-a’-IRS-US-TRS-a (Fig 1.2).

Fig 1.2. HCMV genome structure. (Modified from [6])

2. Capsid
HCMV has an icosahedral-shaped capsid, which is important for both protecting the
large DNA viral genome and releasing the viral genome into host nucleus. There are
at least five proteins involved in capsid formation: UL86 (the major capsid protein),
UL48-49 (the smallest capsid protein, SCP), UL85 (the minor capsid protein), UL46
(minor capsid binding protein), and fragments of UL80 (assembly protein). These
protein components assemble into the capsid through extensive intermolecular
networks, such as formation of disulfide bonds and non-covalent interactions.

3. Tegument
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The tegument layer is formed through sequential adding of proteins, which starts in
the nucleus and completes in the cytoplasm. Previous studies have suggested that
the formation of tegument requires an intact capsid [8]. Tegument proteins play
important roles in regulating viral gene expression and modifying host immune
responses to HCMV infection. For example, tegument protein pp71 activates the
immediate early gene expression to initiate HCMV replication and ppUL83 inhibits
expression of the host proteins associated with induction of interferon response [913]. In addition, tegument proteins are involved in capsids egress by modifying
nuclear cytoskeleton and nuclear membranes [14].

4. Envelope
The envelope of HCMV is a lipid bilayer and viral glycoproteins are embedded in this
lipid bilayer. Mass spectrometry studies have revealed that HCMV virion contains at
least 19 different glycoproteins and some of them are indispensible for viral
replication in vitro, including glycoprotein B (gB), gM/gN and gH/gL [15]. The
relative abundance of these essential glycoproteins follows the order of: gM/gN > gB
> gH/gL.

gM from different strains of HCMV have very few amino acid sequence changes,
while gN from clinical isolates have up to 20% amino acid sequence variability in
the ectodomain whereas the short cytoplasmic tail is conserved. Nearly 67% of gN’s
mass is from carbohydrate, which are almost exclusively O-linked sugars attached to
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the ectodomain. Despite the variation in amino acid sequence, the total O-linked
glycan modification sites are relatively conserved among gN isoforms [16].

The fusion protein gB is a type-I membrane fusion protein with 110kDa ectodomain
disulfide linked to a 55kDa transmembrane domain. gB exists in virion envelope in
the form of homotrimer, which is linked together by inter-chain disulfide bonds
[17]. gB is also heavily glycosylated and it has 50-60kDa of N-linked glycan and at
least one O-linked glycan modification [18].

On the HCMV envelope, gH/gL is decorated by accessory proteins and exists as two
complex forms: gH/gL/gO and gH/gL/UL128/UL130/UL131 (gH/gL/UL128-131).
Compared to gH/gL and UL128-131, gO amino acid sequence is highly diverse
among HCMV strains and the phylogenetic analysis showed that there are 8
genotypes of gO [19]. Within each genotype, the gO sequences are 98-100%
identical, while between groups there are up to 50% differences [19]. The diverse
regions are scattered across the gO sequence but mostly locate at the N-terminus
[64]. Nearly half of the mass of gO is contributed by glycan, the amino acid sequence
divergence may contribute to variation of glycan sites and glycan compositions
among different gO isoforms.

b. HCMV lifecycle
1. Entry and cell tropism
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The very first step of viral replication cycle is entry into host cell. HCMV’s entry
process has high complexity and one unique property of HCMV is that this virus can
infect a broad spectrum of cell types, such as dendritic cells, endothelial cells,
epithelial cells, fibroblast cells, and monocyte/macrophage cells.

The entry event is mediated by envelope glycoproteins: gB, gM/gN, gH/gL/gO and
gH/gL/UL128-131. The gM/gN complex interacts with heparin sulfate
proteoglycans on the host cell surface to facilitate viral particle attachement to the
host cell [28]. As with other human herpesviruses, gB together with gH/gL serve as
the “core” membrane fusion machinery for HCMV. gH/gL complexes trigger gB to
dramatically rearrange its structure and mediate fusion between viral and cellular
membranes [29,30]. However, the mechanisms for how gH/gL complexes interact
or regulate the gB fusogen remain unclear.

The gH/gL complexes, including gH/gL/gO and gH/gL/UL128-131, have big
impacts on the tropism of HCMV. For virus floating outside of cells, gH/gL/gO on the
virion envelope is required for infecting all cell types. It has been shown that
gH/gL/gO can bind to the platelet-derived growth factor receptor-alpha (PDGFR-α)
on fibroblasts through gO [31, 32]. Particularly for infection on certain cell types,
such as leukocytes, epithelial cells, and endothelial cells, gH/gL/UL128-131 is
additionally required. Neuropilin-2 (Nrp2) has been identified as a receptor for
gH/gL/UL128-131 [33]. gH/gL/gO-mediated entry into fibroblast cell occurs
through a rapid macropinocytosis in a pH-independent manner [34]. However, the
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entry into epithelial and endothelial cells, which depend on both gH/gL/gO and
gH/gL/UL128-131, requires low pH and involves endocytosis [35]. Over the years,
many host cell surface proteins have been suggested to function as potential
receptors, co-receptors, or accessory proteins for gH/gL complexes, which
contribute to viral entry. However, the mechanisms of how they affect the entry
event are not well understood [36-39].

2. Delivery of viral genome into the nucleus and initiation of viral gene expression
After fusion between virion envelope and host cell plasma membrane or endosome
membrane, not only the capsid containing viral genome but also the proteins within
tegument layer are released into the cell. The tegument proteins are mainly in
charge of delivering the viral genome to the nucleus and initiating viral gene
expression. For example, tegument proteins pUL47 and pUL48, which are tightly
associated with the nucleocapsid, can interact with microtubules in the cytosol to
accomplish delivery of viral nucleocapsid to the nucleus. Another tegument protein
pp71 can bind and degrade host proteins inside of the nucleus that inhibit viral
genome transcription, thus facilitating the initiation of viral replication.

3. Progeny assembly
The assembly of progeny starts with capsid formation in the nucleus and is followed
by incorporating the viral DNA genome into the capsid through DNA packaging
enzyme (terminase) [23]. After nucleocapsid egress from nucleus to cytoplasm, the
tegument proteins are added to the particle [26]. Once the particle is completely
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tegumented, the immature particle buds into the virion assembly compartment,
which is a complex derived from the endoplasmic reticulum, Golgi apparatus, and
endosomal machinery. The immature particles acquire their envelope along with all
the virion envelope glycoproteins inside of the virion assembly compartment [27].
Afterwards, the fully assembled progeny virus is either released out of the cell or
transported towards the cell-cell interface.

4. Latency and reactivation
Like all herpes viruses, HCMV’s ability of establishing latency is critical for its
lifelong persistence in the host. Compared to acute HCMV infection, which has very
broad cell tropism, latent virus resides in restricted cell types. Based on clinical
study using a highly sensitive PCR approach, it has been found that myeloid lineage
in the peripheral blood is an important site for HCMV latency. More specifically,
CD14+ monocyte population is the dominant carrier of the HCMV latent genome. The
CD34+ cells that reside in bone marrow are also shown to be HCMV genome positive
[40-43].

The reactivation of HCMV gene expression and productive infection is associated
with differentiation of CD34+ cells, which is stimulated by inflammatory cytokines
and/or growth factors [48-49]. The differentiation of CD34+ cells to mature
macrophages and dendritic cells change the level of cellular transcription factors
and these changes lead to viral gene expression.
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c. HCMV genetic variability
HCMV has the largest genome among all known viruses that infect humans. With the
development of Next Generation Sequencing (NGS), researchers in the field started
to look into HCMV sequence in clinical specimens.

Based on clinical samples collected worldwide, NGS analyses showed that HCMV has
significantly higher diversity compared to other human herpesviruses [54]. There
are 21 out of 165 loci scattered in the genome that are hyper-variable across clinical
samples, while the majority are conserved [54-55]. Since most regions are
conserved, the linkage disequilibrium is low among loci, which enables pervasive
recombination between viral genomes. Among the 21 high diversity loci, some of
them encode for glycoproteins that are critical for viral tropism and escape from
host immunity. For example, UL74 encodes for gO, which is involved in viral entry
and spread. The product of the UL11 gene is a membrane glycoprotein, which can
modulate T-cell signaling. For each of the high diversity loci, 2-14 different alleles
exist [153]. It is possible that HCMV utilizes extensive recombination to constantly
diversify the loci that are critical for cell tropism and escaping from immune
responses, while maintaining the rest of the genome that is optimally adapted to the
asymptomatic lifecycle.

High HCMV intra-host diversity has also been described by genomic sequencing
research. This diversity was observed among a range of human hosts, including
healthy adults, children, congenitally infected infants, organ transplant recipients,
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and AIDS patients [56-60]. The analyses also uncovered higher viral genetic
diversity in plasma compared to certain body compartments, which suggests that
the various genomes in the peripheral blood might undergo selection pressure for
fitness in different host compartments [66]. Some potential links have been drawn
between the diversity of viral glycoproteins and dissemination into distinct body
compartments. For example, UL74 (gO) locus diversity may affect dissemination to
certain body compartments by influencing the ratio between gH/gL/gO and
gH/gL/UL128-131 complexes, thus impacting cell tropism [66]. It has also been
found that UL55(gB) genotypes are associated with particular host compartments
[65].

Taken together, these studies highlight the complexity of HCMV genome and
brought a new direction for understanding HCMV’s various pathological outcomes.

d. HCMV immune evasion
The replication and spread of HCMV can induce host immune responses, including
recruitment of natural killer cells, production of neutralizing antibodies, and
activation of CD4+ T-helper cells and CD8+ cytotoxic T cells [67].

HCMV as one of the most ancient human viruses has sophisticated mechanisms for
escaping both innate and acquired immune responses. It has been shown that viral
protein IE2-86 could inhibit transcription of interferon-beta [70]. There is also a list
of viral proteins involved in interfering with MHC-I antigen presentation. For
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example, US2 and US11 translocate MHC heavy chain from ER to cytosol for
proteasome degradation [72]. US3 interacts with MHC-I and leads to ER retention
[73-74]. US6 inhibits peptide transport and prevents viral peptide being loaded to
MHC-I [75]. In addition, UL141 interferes with NK cell activation by retaining
CD155, which is a ligand for the activation receptor on NK cells, inside the ER [78].

For the acquired immune response, HCMV can interfere with T cell stimulation
mainly through viral protein UL144. UL144 interacts with T cell attenuator, which
inhibits T cell proliferation [81]. Interestingly, the UL144 gene has significant strainspecific variability and the amino acid sequences vary up to 20% among HCMV
strains [82-84].

e. HCMV Pathology
HCMV is an opportunistic pathogen and it does not cause disease in healthy people.
However, the infection in hosts with immature or compromised immune system can
cause severe pathology.

1. Congenital and neonatal infection
HCMV is the most frequent among all the congenital viral infections, which account
for more than 40,000 cases in the United States every year. 13% of infected infants
are born with symptoms and 0.5% of the infections are fatal [85]. For the
symptomatic infants, 20% of them suffer from sensorineural hearing loss and the
rest show various symptoms including physical impairment, vision loss, behavioral
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and cognition delays [86]. Clinical studies have shown that the seronegative
mothers who became infected during pregnancy had very high risk of transmitting
the virus to the developing child [87]. Women infected by HCMV before pregnancy
also had the risk of bearing an infected infant, which resulted from infection with a
new strain during conception [88].

2. Hematopoietic stem cell transplantation (HCT) patients
Following HCT, HCMV infection-caused pneumonia is one of the most feared cases at
clinics, and mortality remains high even with treatment [89]. The HCMV infectionassociated gastrointestinal disease is the most common one observed in the clinic
among HCT recipients, which can affect both upper and lower tracts [89]. Since
HCMV has broad cell tropism, the infection also frequently causes retinitis, hepatitis,
and encephalitis. The most important pre-transplant risk factor for HCMV disease is
the serological status of the donor and recipient. The seropositive recipients are
considered as the highest risk, which is mostly caused by HCMV reactivation
diseases [90]. For the cases where the donors are seropositive, recipients have the
risk of getting re-infected by different HCMV strains [90].

3. Solid organ transplantation (SOT) patients
Among SOT patients, HCMV can cause a febrile syndrome with leukopenia and/or
transaminitis. The indirect effects related to HCMV infection include allograft
rejection, decreased graft, and patient death [92]. Compared to HCT patients, HCMV
reactivation diseases in seropositive recipients are less common in SOT patients.
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The highest risk occurs when the organ donor is HCMV seropositive and the
recipient is seronegative.

4. HIV/AIDS patients
HCMV diseases are observed in HIV-1-infected patients whose immune systems are
heavily under attack. Retinitis is the most common clinical manifestation, followed
by gastrointestinal disease and encephalitis [93].

5. Immuno-competent hosts
HCMV infection may occur at any time during lifespan, such as childhood acquisition
in a day care setting, adulthood latent infection reactivation, and transmission
through blood transfusions. Primary infection is typically asymptomatic in immunecompetent hosts. Occasionally, HCMV causes pneumonia or gastrointestinal diseases
[94].

f. Treatment and prevention
Ganciclovir, foscarnet, and cidofovir are the drugs frequently applied for treating
HCMV infection in the clinic. Ganciclovir is a Guanosine analog and after
phosphorylation by HCMV UL97 kinase, it acts as a chain terminator during viral
DNA replication. Cidofovir is a nucleoside monophosphate analog and foscarnet is a
pyrophosphate analog that inhibits viral DNA polymerase activity. Unlike
ganciclovir, neither cidofovir nor foscarnet requires activation by other viral
proteins [94]. Ganciclovir has been tested in both SOT and HIV patients, which could
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be given through intravenous therapy, oral formulations, and locally to the eye for
sight-threatening retinitis [95]. However, the clinical trials for cidofovir have not
been performed in SOT patients.

These drugs have various side effects. For example, ganciclovir’s principal toxicity is
causing neutropenia and the main side effects of foscarnet are renal toxicity and
electrolyte imbalance [96]. It has been observed that HCMV in patients developed
drug resistance to all these three drugs during treatment [97]. The resistance to
ganciclovir has been observed when viral UL97 kinase and viral DNA polymerase
mutations occurred [98]. The resistance mutations against foscarnet and cidofovir
also arise at the DNA polymerase gene [99]. Some of these mutations at the viral
DNA polymerase gene locus could lead to resistance to more than one drug [99].

Considering the tremendous amount of healthcare costs associated with HCMV
infection, much effort has been put into developing vaccines against this virus as a
prevention strategy. The history of vaccine development for HCMV can be traced
back 30 years. However, no HCMV vaccine appears to be approaching imminent
licensure. A variety of strategies have been employed, including live attenuated
vaccines and subunit vaccines, and a number of them have been evaluated in clinical
trials [100].

The first live attenuated vaccine tested in human was developed based on the
laboratory-adapted strain AD169. Later on another live attenuated vaccine based on
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strain Towne was confirmed to elicit neutralizing antibodies as well as CD4+ and
CD8+ T lymphocyte responses. The efficacy of the Towne vaccine was tested in
studies with renal transplant recipients. This vaccine was also tested in a placebocontrolled study in seronegative mothers who had children attending daycare. The
study found that immunization with Towne based vaccine failed to protect these
women from acquiring HCMV infection from their children [103]. However, this
vaccine did protect women with pre-existing immunity against HCMV from getting
re-infected by different strains [103]. Recent evidence indicated that the defect in
Towne live attenuated vaccine might be due to insufficient CD4+ and CD8+ T cell
responses. In order to overcome this defect, adjuvant interleukin-12 (rhIL-12) was
co-administered with live attenuated Towne vaccine and it is currently under
clinical trial [104]. In addition, chimeric viruses between strain Towne and Toledo
were generated as live attenuated vaccines. Four of these Towne/Toledo chimeric
vaccines were tested in a clinical trial and all of them were well tolerated with no
sign of virus shedding in the blood and body fluids [105]. However, the major
concern or risk for live attenuated vaccines is that they may establish latent HCMV
infections.

Subunit vaccines are designed against specific immunogenic viral proteins, which
are expressed by various techniques and tested either alone or in combination.
Based on clinical observations among HCMV-seropositive individuals, up to 70% of
neutralizing antibodies respond to gB [106], which makes gB a promising candidate
for subunit vaccine development. The vaccines based on gB demonstrated
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protection against HCMV infection disease in murine and guinea pig models [107].
In current clinical trials, soluble gB ectodomain expressed in Chinese hamster ovary
(CHO) cells are purified and combined with adjuvants MF59 or alum as vaccines
[108]. These vaccines are currently under test among seronegative adults, a limited
number of toddlers, young HCMV-seronegative women, and renal transplant
patients who are waiting for transplantation. Based on the results reported to date,
the level of gB-specific antibodies and virus neutralizing activity after 3 doses
exceeded those observed in HCMV-seropositive controls [109-111].

pp65 has been identified as a target for subunit vaccine because it is the dominant
trigger for CD8+ T cell responses [113-114]. During clinical trial, pp65 vaccine
recipients were observed with a similar level of HCMV-specific CD8+ cytotoxic T cell
responses as the seropositive controls [115]. The pp65 vaccine is also currently
under clinical trial in a trivalent formulation together with gB and IE1 vaccines
[115].

Focus of the dissertation
Human cytomegalovirus (HCMV) glycoproteins H and L (gH/gL) can be bound by
either gO or UL128, UL130, and UL131 proteins to form complexes: gH/gL/gO and
gH/gL/UL128-131, which facilitate viral entry and spread [122-127, 129-132]. The
epitopes on gH/gL in two complexes are important targets of neutralizing
antibodies [166-170]. Strains of HCMV vary dramatically in their levels of gH/gL/gO
and gH/gL/UL128-131. The UL74 locus that encodes for gO is one of the most
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diverse loci among HCMV strains. Most phylogenetic groupings indicate gO has 8
genotypes, which differ in 10% to 30% of amino acid sequences [64, 135]. The
diverse regions of gO predominately locate at the N-terminus and these amino acid
polymorphisms can potentially affect the N-linked glycan sites on gO [64].

The two major questions addressed in this dissertation include:
§

What are the mechanisms behind gH/gL complex assembly differences
between strains?

§

How do natural inter-strain variations in the amino acid sequence of gO
influence the biology of HCMV?

The studies in Chapter 2 address the first question by utilizing recombinant viruses
in which the UL74 (gO) ORF was swapped. I picked strain TR to represent strains
with gH/gL/gO as the dominant gH/gL complex on the envelope, and strain Merlin
(ME) represented for gH/gL/UL128-131-rich viruses. I observed that swapping
UL74 (gO) had no effect on gH/gL complexes assembly for both strains. To explore
whether the abundance of viral proteins could influence gH/gL complex formation, I
applied a quantitative immunoprecipitation approach and revealed that gO
expression level was 20-fold lower in ME compared to TR. Overall, strain variations
in the assembly of gH/gL complexes are mostly due to the viral protein expression
level difference and gO amino acid sequence does not affect the gH/gL complexes
assembly process.
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The Chapter 3 summarizes my results for investigating the second question. I
constructed heterologous gO recombinants with 6 out of 8 genotypes (GT) and
analyzed them in both strain TR and strain ME backgrounds. I found that gO
isoforms could impact viral entry, spread, and sensitivity to anti-gH neutralizing
antibodies and these effects were subjected to epistatic global strain genetic
differences. Characterization of these gO recombinants has also revealed that
gH/gL/gO utilizes different mechanisms for facilitating cell-free and cell-to-cell
spread, and gH/gL/gO performs its functions in viral attachment and fusion in a
separate manner.

In summary, this dissertation explored the significance of gO diversity in critical
aspects of HCMV biology and highlighted the epistatic effects in HCMV phenotype
determination. These findings may provide information for better understanding of
HCMV pathology and bring novel insights on vaccine design strategy.
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Chapter II. Expression levels of glycoprotein O
(gO) vary between strains of Human
Cytomegalovirus, influencing the assembly of
gH/gL complexes and virion infectivity.

This chapter is modified version of the manuscript published
in Journal of Virology in May 2018; 92: e00606-18.
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Introduction
Human Cytomegalovirus (HCMV) is widely spread through the world and it is found
in approximately 60% of adults in developed countries and in 100% of adults in
developing countries [116-119]. HCMV is an opportunistic pathogen and
immunocompromised individuals, such as HIV patients, transplant recipients under
immunosuppression treatments can suffer severe HCMV infection related
pathologies, including gastroenteritis, encephalitis, retinitis, and vasculopathies. The
congenital infection of HCMV is a significant cause of congenital neurological
impairments and sensorineural hearing loss. The transmission of HCMV is mainly
through body fluid, such as urine and saliva. Once infection is established, the virus
spreads throughout the body, infecting many of the major somatic cell types,
neurons, and leukocytes.

Much focus has been on the gH/gL complexes, which likely engage cell receptors
and promote infection by contributing to the gB-mediated membrane fusion event
or through activating cell signaling pathways [120-122]. During virus assembly, the
HCMV UL128-131 proteins and gO compete for binding to gH/gL to form the
pentameric complex gH/gL/UL128-131 or the trimeric complex gH/gL/gO.
Structural studies involving purified soluble complexes showed that gO and UL128
can each make a disulfide bond with cysteine 144 of gL, and this was suggested to be
the basis of the competitive assembly of the complexes [123]. However, Stegmann et
al. demonstrated that mutant gO lacking the cysteine implicated in the disulfide
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bond with gL formed intact and functional gH/gL/gO [124]. This suggests that gO
can engage in extensive non-covalent interactions with gH/gL. The gH/gL/UL128131 complex is dispensable for infection of cultured fibroblasts and neuronal cells
but is required for infection of epithelial and endothelial cells and monocytesmacrophages [125-129]. In contrast, gH/gL/gO is critical for infection of all cell
types [130-133]. Both complexes likely interact with cell receptors. gH/gL/gO can
bind platelet-derived growth factor receptor alpha (PDGFRα) through the gO
subunit, and this interaction is critical for infection of fibroblasts [31-32, 134].
Epithelial and endothelial cells do not express PDGFRα, but blocking of gH/gL/gO
with either neutralizing antibodies or soluble PDGFRα can inhibit infection of these
cells, suggesting the existence of other gH/gL/gO receptors [31-32]. Receptors for
gH/gL/UL128-131 might include epidermal growth factor receptor (EGFR) (also
known as ErbB1) and β1 or β3 integrins, and these interactions may induce
signaling cascades critical for infection of selected cell types, such as epithelial and
endothelial cells and monocytes-macrophages [31, 35].

Zhou et al. reported that the amounts of gH/gL/gO and gH/gL/UL128-131 in the
virion envelope differ dramatically among strains of HCMV and this difference
affects the infectivity of the virions [64,133]. The major results of those studies were
that 1) Merlin (ME) virions contained gH/gL mostly in the form of gH/gL/UL128131, whereas TR and TB 40/E (TB) virions had mostly gH/gL/gO; 2) in terms of
“total gH/gL,” the amount of gH/gL/gO in TR and TB virions was larger than the
amount of gH/gL/UL128-131 in ME virions; 3) the infectivity of all three strains on
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both fibroblasts and epithelial cells correlated with the amount of gH/gL/gO; and 4)
when the expression of UL128-131 was suppressed in ME, virions contained
dramatically less gH/gL/UL128-131 but only slightly more gH/gL/gO. The latter
point was especially curious since the model that gO and UL128-131 proteins
compete for binding to gH/gL would predict that the fraction of gH/gL normally
bound by UL128-131 would, in their absence, be bound by gO instead. This
discrepancy could be explained by differences in the stoichiometric expression of
gH/gL, gO, and UL128-131 between strains. An alternative hypothesis was
suggested by the fact that there are at least eight alleles of the UL74 gene that
encodes gO [135]. The amino acid sequence of gO among these eight genotypes can
vary between 10 and 30%, and this could affect competition with UL128-131 for
binding to gH/gL. Both of these non-mutually-exclusive hypotheses were addressed
in this chapter.

Results
Strains of HCMV display different patterns of glycoprotein expression and
trafficking to virion assembly compartments.
The dramatic differences in the compositions of gH/gL complexes in TR and ME
virions described previously by Zhou et al. [64, 133] suggested corresponding
differences in glycoprotein expression and/or the trafficking of glycoproteins to
virion assembly compartments (ACs). To address these possibilities, cells were
infected for 2 days (Fig 2.1A) or 5 days (Fig 2.1B) with TR or ME, and steady-state
amounts of viral proteins were compared by immunoblotting. At 2 days
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postinfection (dpi), immediate early protein 1/2 (IE1/2) levels were similar for both
TR and ME, consistent with an equal multiplicity of infection. At 5 dpi, the levels of
the virion structural proteins major capsid protein (MCP), gB, gH, and gL were also
very similar between the two strains. In contrast, ME-infected cells contained
dramatically more UL128-131 protein than did TR-infected cells. The UL148 protein
was also included in these analyses because it was recently described as an
endoplasmic reticulum (ER) chaperone protein that influences the ratio of gH/gL
complexes [136]. In TR-infected cells, an anti-UL148 antibody detected a prominent
35-kDa protein species, consistent with the previous description of the UL148
protein [136]. This 35-kDa species was not detected in ME-infected cells. Instead,
ME-infected cells contained two species that were less abundant and of higher and
lower electrophoretic motilities than the single UL148 species detected in TRinfected cells. The basis of the apparent size difference was not characterized but
could reflect differences in translational start/stop codon usage, splicing of the
UL148 mRNA, or posttranslational modifications of the UL148 protein between
strains. Overall, the pattern of expression of the UL128-131 and UL148 proteins
correlated well with the previously described pentamer-rich nature of ME virions
and the trimer-rich nature of TR virions [64, 133]. Note that the expression of gO
was not addressed in these analyses because the gO amino acid sequence
differences between strains affect antibody recognition and preclude direct
comparison [64].
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Fig 2.1 Comparison of protein expression between TR and ME. nHDF were infected with 1
PFU/cell of TR or ME. At day 2 (A) or day 5 (B), total cell extracts were separated by
reducing SDS-PAGE and analyzed by immunoblot analysis probing for immediate early
protein 1/2 (IE1/2), major capsid protein (MCP), gB, gH, gL, UL128, UL130, UL131, or
UL148. Arrowheads indicate the positions of the cleaved 100-kDa and 55-kDa fragments of
gB.

Trafficking of gH/gL from the ER to trans-Golgi network (TGN)-derived assembly
compartments was assessed by treating the infected-cell extracts at 5 dpi with
either endoglycosidase H (endo H) or peptide N-glycosidase F (PNGase F) and then
analyzing gH and gL by immunoblotting (Fig 2.2). The majority of gH and gL in TR26

infected cells was endo H resistant, consistent with efficient transport from the ER
to trans-Golgi network-derived ACs. In contrast, most of the gH and gL in MEinfected cells was sensitive to endo H digestion. In HFFFtet cells, which repress
transcription from the UL128-131 locus [64, 137], there was even less endo Hresistant gH and gL. This suggested that the bulk of gH/gL trafficked to ACs in MEinfected neonatal human dermal fibroblasts (nHDF), which allow UL128-131
expression, represented gH/gL/UL128-131 and is consistent with previous
observations that (i) the bulk of gH/gL in the ME virion is pentamers and (ii) the
loss of gH/gL in the form of pentamers in ME-T virions due to the repression of the
UL128-131 proteins is apparently not fully compensated for by the formation of
complexes with gO [64, 133].

Fig 2.2 Analysis of ER-to-trans-Golgi compartment trafficking of glycoproteins in TR- or MEinfected cells. Extracts of nHDF infected with TR or ME or HFFFtet cells infected with ME
were treated with endoglycosidase H (H) or PNGase F (F) or left untreated (U) and then
separated by reducing SDS-PAGE and analyzed by immunoblot analysis probing for gH or
gL. Arrowheads indicate the positions of the faster-migrating, deglycosylated species.
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Differences in amino acid sequence of gO between TR and ME do not affect the
infectivity of cell-free virus.
The predicted amino acid sequence of gO differs by 25% between TR and ME. This
sequence divergence precluded direct comparison of gO expression levels because
antibodies do not cross-react [64]. Furthermore, these sequence differences could
potentially affect the ability of the distinct gO isoforms to compete with the UL128131 proteins for binding to gH/gL (thus influencing the amounts of gH/gL
complexes in the mature virion envelope) or the function(s) of gO during entry, such
as binding PDGFRα or other receptors. To address these possibilities, bacterial
artificial chromosome (BAC) recombineering methods were used to replace the gO
open reading frame (ORF) (UL74) of TR with the analogous sequences from ME, and
visa versa, to generate recombinant viruses denoted TR_MEgO and ME_TRgO.
Zhou et al. demonstrated a positive correlation between the infectivity of HCMV
virions and the amounts of gH/gL/gO in the virion envelope [133]. To assess the
effects of gO sequences on infectivity, cell-free virus stocks of the parental wild type
and heterologous gO recombinants were analyzed by quantitative PCR (qPCR) to
determine the number of virions, and infectivity was determined by a plaque assay.
No difference in particles/PFU was observed between TR and the corresponding
recombinant TR_MEgO (Fig 2.3) or between ME and the corresponding recombinant
ME_TRgO (Fig 2.3). When ME-based HCMV was grown in HFFFtet cells, which
repress UL128-131 expression, the resultant virions, ME-T and ME-T_TRgO, were
dramatically more infectious, as shown previously [133, 137], but consistently,
there were no differences due to the isoform of gO expressed (Fig 2.3). In parallel
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analyses, the amounts of gH/gL complexes were analyzed by nonreducing
immunoblot probing for gL to detect intact, disulfide-linked gH/gL/gO and disulfidelinked gH/gL/UL128 (note that UL130 and UL131 are not disulfide linked to the
intact pentamer complex and are thus separated by SDS-PAGE) (Fig 2.4). Consistent
with our previous reports [64, 133], TR virions contained much larger amounts of
total gH/gL, mostly in the form of gH/gL/gO, whereas ME virions contained less
gH/gL, mostly as gH/gL/UL128-131. Repression of the UL128-131 proteins (ME-T)
drastically reduced the amount of gH/gL/UL128-131 and increased the amount of
gH/gL/gO. However, note that the amount of gH/gL/gO in ME-T virions was still
smaller than the amount of gH/gL/UL128-131 in ME virions, indicating that the
repression of UL128-131 was not fully compensated for by gO. In no case did the
expression of the heterologous gO isoform detectably influence the amounts of
gH/gL complexes in HCMV virions. Together, these results suggest that the amino
acid sequence differences between TR and ME gO do not influence gH/gL complex
assembly or the function of gO in entry into fibroblasts.
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Fig 2.3 Specific infectivity of parental and TR-ME heterologous gO recombinants.
Extracellular virions of TR, TR_MEgO, ME, ME_TRgO, ME-T, or ME-T_TRgO were analyzed by
quantitative PCR for viral genomes, and PFU were determined by a plaque assay on nHDF.
Average particle/PFU ratios from at least 4 independent experiments are plotted. Error
bars represent standard deviations.

Fig 2.4 Immunoblot analysis of gH/gL complexes in parental viruses and TR-ME
heterologous gO recombinants. Extracellular virion extracts of TR, TR_MEgO, ME, ME_TRgO,
ME-T, or ME-T_TRgO were separated by reducing (A and B) or nonreducing (C) SDS-PAGE
and analyzed by immunoblot probing for major capsid protein (A) or gL (B and C).
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ME expresses less gO during replication than does TR.
The heterologous gO recombinants allowed comparison of gO expression levels
between TR and ME. In the first analyses, cells infected with the parental virus or
the heterologous gO recombinants were analyzed by reducing immunoblot analysis
using TR- and ME-specific anti-gO antibodies [64] (Fig 2.5). TR-specific gO
antibodies detected two bands in TR-infected cells, a prominent species migrating
just above the 100-kDa marker and a minor, more diffuse species migrating at
approximately 130 to 140 kDa. The ME-specific antibodies detected similarly
migrating bands in TR_MEgO-infected cells; however, their relative abundances
appeared more equal. No similar bands were detected in cells infected with ME or
ME_TRgO analyzed with either gO antiserum. The failure to detect either isoform of
gO in cells infected with ME-based HCMV suggested that the protein expression
level from the UL74 locus of ME was lower than that in TR.

To directly compare differences in glycoprotein expression between TR and ME,
infected cells were labeled with [35S]methionine-cysteine for 15 min and then
analyzed by immunoprecipitation with antipeptide antibodies specific for gH, gL, or
gO, followed by SDS-PAGE and band density analysis (Fig 2.6 and Tables 1 and 2).
Two approaches were taken to allow direct quantitative comparisons of labeled
proteins between extracts. First, cell extracts were denatured and reduced with
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Fig 2.5 Immunoblot analysis of gO expression in cells infected with parental viruses and TRME heterologous gO recombinants. nHDF were infected with 1 PFU/cell of TR, TR_MEgO,
ME, or ME_TRgO. At day 5, total cell extracts of infected cells were separated by reducing
SDS-PAGE and analyzed by immunoblot probing for TRgO, MEgO, MCP, or actin.

SDS-dichlorodiphenyltrichloroethane (DDT) prior to immunoprecipitation to allow
maximum epitope access by the antipeptide antibodies. Second, for each analysis,
multiple immunoprecipitation reactions were performed in parallel with increasing
amounts of protein extract input to ensure that antibodies were not limiting. In
these experiments, expression levels of gH were nearly identical between TR and
ME, and the gL expression level was approximately 4-fold higher for TR than for ME,
but the gO expression level was strikingly 27-fold higher for TR than for ME (Fig
2.6A and Table 2.1). To address the possibility that the MEgO-specific antibodies
were simply less efficient at capturing MEgO from ME extracts, similar experiments
were performed with the TR-ME heterologous gO recombinants (Fig 2.6B and Table
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2.2). Again, gH and gL levels were similar between TR_MEgO and ME_TRgO, but gO
levels were approximately 20-fold higher for the TR-based virus. To address the
hypothesis that differences in gO expression between TR and ME reflect differences
in protein turnover, the [35S]methionine-cysteine label was chased for up to 6 h (Fig
2.7). The patterns of gH detection over the chase time were very similar for both TR
and ME samples. In both cases, the amounts of labeled gH dropped to 60% after 3 h
and to 30 to 40% after 6 h. The pattern of gO detection for both TR and ME was
comparable to that of gH detection. Together, these results confirmed that MEinfected cells express less gO than do TR-infected cells and suggested differences in
early steps of expression, such as mRNA transcription, translation, or rapid ERassociated degradation, which can degrade proteins in the time scale of minutes
[138].
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Fig 2.6 Quantitative comparison of glycoprotein expression in TR- and ME-infected cells.
nHDF were infected with 1 PFU/cell of TR or ME (A) or TR_MEgO or ME_TRgO (B). At 5 dpi,
infected cells were metabolically labeled with [35S]cysteine-methionine for 15 min, and
membrane proteins were extracted in 1% Triton X-100. All samples were adjusted to 2%
SDS–30 mM DTT, heated to 75°C for 10 min, cooled to room temperature, and then diluted
35-fold. Parallel immunoprecipitations were performed, in which equal amounts of anti-gH,
gL, or gO (TR- or ME-specific) antibodies were reacted with 3-fold-increasing amounts of
protein extract as the input, and precipitated proteins were analyzed by SDS-PAGE.
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Table 2.1 Quantitative comparison of glycoprotein expression in TR- and ME-infected cellsd

aSeven microliters of rabbit antipeptide serum per immunoprecipitation reaction mixture.
bPreparation of radiolabeled cell extracts is described in the legend to Fig 2.6 and in

Materials and Methods.
cPixel density of bands shown in Fig 2.6A as determined using ImageJ version 1.48.
dND, band density not detected.
eDensity divided by the predicted number of methionine (met) and cysteine (cys) residues:

TRgH (17 met, 13 cys), MEgH (17 met, 14 cys), TRgL (3 met, 10 cys), MEgL (3 met, 10 cys),
TRgO (16 met, 6 cys), MEgO (18 met, 6 cys).
fAdjusted density of TR divided by adjusted density of ME.
gAverage fold difference between TR and ME ± standard deviation.
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Table 2.2 Quantitative comparison of glycoprotein expression in TR_MEgO- and ME_TRgOinfected cellsd.

aSeven microliters of rabbit antipeptide serum per immunoprecipitation reaction mixture.
bPreparation of radiolabeled cell extracts is described in the legend to Fig 2.6 and in

Materials and Methods.
cPixel density of bands shown in Fig. 6B as determined using ImageJ version 1.48.
dND, band density not detected.
eDensity divided by the predicted number of methionine (met) and cysteine (cys) residues:

TRgH (17 met, 13 cys), MEgH (17 met, 14 cys), TRgL (3 met, 10 cys), MEgL (3 met, 10 cys),
TRgO (16 met, 6 cys), MEgO (18 met, 6 cys).
fAdjusted density of TR_MEgO divided by adjusted density of ME_TRgO.
gAverage fold difference between TR_MEgO and ME_TRgO ± standard deviation.
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Fig 2.7 Analysis of glycoprotein turnover in TR- and ME-infected cells. nHDF were infected
with 1 PFU/cell of TR or ME. At 5 dpi, infected cells were metabolically labeled with
[35S]cysteine-methionine for 15 min, and the label was then chased for 0, 10, 60, 180, or 360
min. Membrane proteins were extracted in 1%Triton X-100, adjusted to 2% SDS–30mM
DTT, heated to 75°C for 10 min, cooled to room temperature, and then diluted 35-fold.
Immunoprecipitation was performed with anti-gH and -gO (TR- or ME-specific) antibodies,
and precipitated proteins were analyzed by SDS-PAGE. Band densities were determined
relative to the 0-min chase time. Results shown are representative of data from 4
independent experiments.

Overexpression of gO during ME replication increases gH/gL/gO assembly and
virus infectivity.
To directly test the hypothesis that the low abundance of gH/gL/gO in ME virions
was due not simply to competition from the UL128-131 proteins but also to low gO
expression, adenovirus (Ad) vectors were used to increase gO levels during ME
replication. Ad vectors expressing green fluorescent protein (GFP) were used to
control for potential effects of the Ad vectors themselves. Consistent with data from
the above-described analyses, gO levels were below the limits of immunoblot
detection in ME-infected nHDF or HFFFtet cells, but gO was readily detected in cells
superinfected with AdMEgO (Fig 2.8A). The overall expression of gL in ME-infected
cells was reduced by the presence of either Ad vector (Fig 2.8A). In the case of the
control AdGFP, the lower intracellular gL level correlated with reduced levels of
gH/gL/gO complexes in virions from HFFFtet cells (ME-T) (Fig 2.8B), and this in
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turn correlated with reduced infectivity (i.e., increased particle/PFU ratio) (Fig 2.9).
The “Ad effect” on virion gH/gL levels and infectivity was less apparent in human
foreskin fibroblast (HFF) cells (ME), perhaps masked by the overall larger amounts
of gH/gL and the much lower infectivity of these virions (Fig 2.8B and 2.9).
Controlling for the Ad effect, AdMEgO expression in HFFFtet cells increased the
amounts of gH/gL/gO in ME-T virions compared to AdGFP, and this resulted in a 6fold enhancement of infectivity, beyond the 40-fold enhanced infectivity resulting
from the repression of UL128-131 alone (Fig 2.8B and 2.9). In contrast, AdMEgO
expression had little effect on the virions from HFF cells.

FIG 2.8 Ad vector overexpression of gO during ME replication. nHDF or HFFFtet cells were
infected with ME for 2 days and then superinfected with Ad vectors expressing either GFP
or MEgO for an additional 4 days. Extracts of infected cells (A) or extracellular virions (B)
were separated by reducing (A and B, top) or nonreducing (B, bottom) SDS-PAGE and
analyzed by immunoblot probing for MEgO, actin, MCP, or gL, as indicated to the right.
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FIG 2.9 Specific infectivity of ME virions produced under conditions of gO overexpression.
nHDF or HFFFtet cells were infected with ME for 2 days and then superinfected with Ad
vectors expressing either GFP or MEgO for an additional 4 days. Extracellular virions from
nHDF (ME) or HFFFtet (ME-T) cells were analyzed by quantitative PCR for viral genomes,
and PFU were determined by a plaque assay on nHDF. Shown are average particle/PFU
ratios of virions produced in 2 independent experiments, each analyzed in triplicate. Error
bars represent the standard deviations. Asterisks above fold differences indicate a P value
of <0.03 (determined by Student’s unpaired t test [2 tailed]).

Discussion
Recent population genetic studies have demonstrated a greater degree of genetic
diversity of HCMV in clinical specimens than had been previously appreciated [54,
61, 139]. The cell type and propagation methods likely narrow the resultant
genotypes by purifying selection [140-141]. During propagation in cultured
fibroblasts, inactivating mutations in the UL128-131 ORFs are rapidly selected in a
BAC clone of ME, and this selective pressure can be relieved by transcriptional
repression of the UL131 promoter, which reduces the expression of pentameric
gH/gL/UL128-131 [137]. In contrast, the UL128-131 ORFs are more stable in BAC
clones of strains TR and TB [141-142]. The UL128-131 ORF of TB contains a single

39

nucleotide polymorphism (SNP) relative to ME that reduces the splicing of the
mRNA encoding the UL128 protein, which may help stabilize the UL128-131 ORFs
through reduced expression of gH/gL/UL128-131 [142]. However, TR is identical to
ME at this nucleotide position, and recombinant ME in which the UL128-131 locus
was replaced with the UL128-131 sequences from TR was as sensitive to the
selective inactivation of the locus as wild-type ME [142]. Together, these
observations suggest that factors beyond the expression levels of the UL128-131
proteins can influence the selective pressures on the UL128-131 ORFs.

The results reported here demonstrated that TR and ME differ in the stoichiometry
of expression of gO and UL128-131, and this seems to be a major factor determining
the abundances of gH/gL/gO and gH/gL/UL128-131 in the virion envelope and the
infectivity of cell-free virions. The steady-state levels of gH/gL in fibroblasts infected
with TR and ME were found to be comparable, but ME-infected cells contained more
UL128-131 than did TR-infected cells. In ME-infected cells, most of the gH/gL was in
an ER-associated form, whereas TR-infected cells contained a large amount of Golgi
compartment-associated gH/gL. This correlated well with previous observations
that TR contained more total gH/gL than did ME virions [64, 133]. The amount of
Golgi compartment-associated gH/gL in ME-infected cells was reduced when the
expression of the UL128-131 proteins was repressed, consistent with the
observation that most of the gH/gL in ME virions was in the form of gH/gL/UL128131 [64,133]. Comparison of gO expression levels between strains was complicated
because the amino acid sequence differences between genotypes affected antibody
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recognition [64]. To circumvent this caveat, HCMV recombinants were engineered,
in which the UL74(gO) ORFs of TR were replaced with the homologous sequences of
ME, and vice versa. This approach allowed the analysis of the expression of both gO
isoforms in both genetic backgrounds, eliminating the possibility that the results
were due to differences in antibody-antigen affinities. Immunoblot and
radiolabeling experiments clearly demonstrated that ME infected cells contained
less gO than did TR-infected cells. The overexpression of gO during ME replication
had no effect on the levels of gH/gL/gO or the infectivity of the virions unless
UL128-131 proteins were also transcriptionally repressed, and even then,
gH/gL/gO levels and infectivity were only modestly enhanced. Together, these
results underscore the competition between gO and UL128-131 for binding to
gH/gL and suggest that other factors may influence the efficiency of gH/gL/gO
assembly.

The molecular mechanisms underpinning the discrepancy between TR and ME in
the expression UL128-131 and gO remain unclear. As mentioned above, Murrell et
al. described a SNP in the TB UL128-131 locus that affected mRNA splicing, in part
explaining the lower expression levels of these proteins in TB [142]. However, this
splicing effect does not explain the difference in UL128-131 expression levels
between TR and ME, since this nucleotide position is conserved between these
strains. For gO, the radiolabeling analyses reported in Fig 2.6 and 2.7 suggest that
the differences are due to early events in UL74(gO) expression, such as
transcription, mRNA processing/stability, translation, or rapid ER-associated
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degradation, occurring in the time scale of minutes [138]. Attempts to analyze
UL74(gO) mRNA levels between TR and ME by quantitative reverse transcriptionPCR (RT-PCR) were complicated by the fact that HCMV genomes contain many
overlapping RNA polymerase II (RNAPII) transcription units that vary between
strains [143, 144]. It is interesting that ME-infected cells contained less UL148 than
did TR-infected cells. UL148 was first described as an ER-resident chaperone
protein that promotes the assembly of gH/gL/gO [136]. The mechanism may well
involve interactions between UL148 and the cellular ER-associated degradation
pathway (C. Nguyen, M. Siddiquey, H. Zhang, and J. Kamil, presented at the 42nd
International Herpesvirus Workshop, Ghent, Belgium, 2017).

The TR-ME heterologous gO recombinant viruses also allowed analysis of the effects
of gO amino acid sequence differences on the assembly of gH/gL complexes and the
function of gO in entry. No differences were observed between TR and TR_MEgO or
between ME and ME_TRgO in either the amounts of gH/gL complexes in virions or
cell-free infectivity. These results argue against the notion that the amino acid
sequence differences between gO genotypes affect interactions with gH/gL or the
binding of the fibroblast entry receptor PDGFRα. Interestingly, Kalser et al. showed
that replacing the endogenous gO protein of TB with the gO protein from Towne did
not alter replication in cultured fibroblasts but enhanced replication in epithelial
cell cultures [145]. Thus, it may be that gO sequence variation affects interactions
with receptors other than PDGFRα that mediate infection of epithelial cells.
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Laib-Sampaio et al. reported that mutational disruption of UL74(gO) expression in
ME had little effect on replication unless the UL128-131 locus was also disrupted
[132]. Those authors suggested that the spread of ME was mediated principally by
gH/gL/UL128-131 in a cell-associated manner, but when UL128-131 was
inactivated, spread could also occur in a cell-free manner, mediated by gH/gL/gO.
This is in stark contrast to the dramatic phenotype reported for a gO-null TR mutant
[130]. Our finding that the level of expression of gO by ME is low compared to that
by TR may provide a partial explanation for these different gO-null phenotypes.

It remains unclear whether the described difference in gO expression between TR
and ME represents a bona fide variation that naturally exists between HCMV
genotypes in vivo or reflects differential selection on de novo mutations that
occurred during the independent isolation of these strains from clinical specimens.
It seems clear that serial propagation of ME in cultured fibroblasts selects for de
novo mutations that reduce or abolish the robust expression of the UL128-131
proteins [137, 141]. The selective pressure that fixes these mutations in the culture
population may be explained by data from the specific infectivity analyses reported
here (Fig 2.3 and 2.9) and by Zhou et al. [133]. In both analyses, the specific
infectivity of TR was measured at approximately 100 to 200 particles/PFU, whereas
ME was 30- to 50-fold less infectious. Repression of the UL128-131 proteins
enhanced the infectivity of ME (“ME-T”) to levels comparable to those of TR
(approximately 100 particles/PFU). While the infectivities of ME-T and TR virions
were comparable, ME-T virions still contained far less gH/gL/gO than did TR virions
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(Fig 2.4)[133]. Ad vector overexpression of gO enhanced the infectivity of ME only
6-fold beyond the enhancement due to UL128-131 repression alone (Fig 2.8 and
2.9). Together, these observations seem to suggest that in vitro selective pressures
for reduced UL128-131 expression are much more pronounced than any for
enhanced gO expression. Thus, it is possible that the difference in gO expression
between HCMV TR and ME is derived not from the selection of de novo mutations
occurring during propagation in culture but from nonselective, random sampling of
the multitude of different genotypes that likely preexist in clinical specimens [54,
61, 139]. Distinguishing between these possibilities will require clear identification
of the genomic sequences that determine gO expression levels.

Materials and methods
Cell lines. Primary neonatal human dermal fibroblasts (nHDF; Thermo Fisher
Scientific), MRC-5 fibroblasts (ATCC CCL-171; American Type Culture Collection),
and HFFFtet cells (which express the tetracycline [Tet] repressor protein; provided
by Richard Stanton) [137] were grown in Dulbecco’s modified Eagle’s medium
(DMEM; Thermo Fisher Scientific) supplemented with 6% heat-inactivated fetal
bovine serum (FBS; Rocky Mountain Biologicals, Inc., Missoula, MT, USA) and 6%
bovine growth serum (BGS; Rocky Mountain Biologicals, Inc., Missoula, MT, USA).
Human cytomegaloviruses. All HCMV strains were derived from bacterial artificial
chromosome (BAC) clones. The BAC clone of TR was provided by Jay Nelson
(Oregon Health and Sciences University, Portland, OR, USA) [146]. The BAC clone of
Merlin (ME) (pAL1393), which carries tetracycline operator sequences in the
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transcriptional promoter of UL130 and UL131, was provided by Richard Stanton.
[137]. Infectious HCMV was recovered by electroporation of BAC DNA into MRC-5
fibroblasts, as described previously by Wille et al. [130]. Cell-free HCMV stocks were
produced by infecting HFF or HFFFtet cells at 2 PFU per cell. At 8 to 10 days
postinfection (when cells were still visually intact), culture supernatants were
harvested, and cellular contaminants were removed by centrifugation at 1,000 X g
for 10 min and again at 6,000 X g for 10 min. Stocks were judged to be cell free by
the lack of calnexin and actin by Western blot analyses and then stored at -80°C.
Freeze-thaw cycles were avoided. PFU were determined by plating a series of 10fold dilutions of each stock onto replicate cultures of HFF for 2 h at 37°C and
replacing the inoculum with DMEM supplemented with 5% FBS and 0.6% SeaPlaque
agarose (to limit cell-free spread). Plaques were counted by light microscopy 3
weeks after infection.

Heterologous UL74(gO) recombinant HCMV. A two-step BAC recombineering
process was performed as previously described [137]. In the first step, the
endogenous UL74 ORF from the start codon to the stop codon of both TR and ME
was replaced by a selectable marker. Briefly, cultures of Escherichia coli SW102
containing either the BAC clone of TR or ME were grown at 32°C until an optical
density at 600 nm (OD600) of 0.55 was reached. Recombination genes were induced
by incubation at 42°C for 15min. The purified PCR product containing the
KanR/LacZ/RpsL selectable marker cassette flanked by sequences homologous to
80 bp upstream and downstream of the TR or ME UL74 ORF was electroporated
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into the bacteria, and cultures were incubated for 1 h at 32°C and then selected on
medium containing kanamycin (15 μg/ml), isopropyl-β-D-thiogalactopyranoside
(IPTG) (50 μM), 5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside (X-gal) (20
μg/ml), and chloramphenicol (12.5 μg/ml). First-step primer sequences were 5’CTTGGTGGACTATGCTTAACGCTCTCATTCTCATGGGAGCTTTTTGTATCGTATTAC
GACATTGCTGTTTCCAGAACTCCTGTGACGGAAGATCACTTCG-3’ and 5’CGACCAGAATCAGCAGTGAGTACACGCAGGCAAGCCAAACCACAAGGCAGACGGACGGT
GCGGGGTCTCCTCCTCTGTCCTGAGGTTCTTATGGCTCTTG-3’ for TR and 5’CCTGGTGGACTATGCTTAACGCTCTCATTCTGATGGGAGCTTTTTGTATCGTATTACGAC
ATTGCTGCTTCCAGAACTCCTGTGACGGAAGATCACTTCG-3’ and 5’CGACCAGAATCAGCAGTGAGTACACGCAGGCAAACCAAACCACAAGGCAGACGGACGGT
GCGGGGTCTCCTCCTCTGTACTGAGGTTCTTATGGCTCTTG-3’ for ME.

In the second step, the selectable marker cassette in the TR and ME first-step
intermediate BACs was replaced with the UL74(gO) sequence from the heterologous
strain. Briefly, E. coli cultures were prepared for recombination as described above
for step 1 and electroporated with purified PCR products containing the UL74 ORF
from the TR or ME strain flanked by sequence homologous to 80 bp upstream and
downstream of the opposite strain. Transformed E. coli cells were selected for the
removal of the KanR/LacZ/RpsL cassette by growth on medium containing
streptomycin (1.5 mg/ml), IPTG (50 μM), X-gal (20 μg/ml), and chloramphenicol
(12.5 μg/ml). Primers used to generate the second-step PCR product were 5’GCCTGGTGGACTATGCTTAACGCTCTCATTCTGATGGGAGCTTTTTGTATCGTATTACGA
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CATTGCTGCTTCCAGAACTTTACTGCAACCACCACCAAAG-3’ and 5’CGACCAGAATCAGCAGTGAGTACACGCAGGCAAACCAAACCACAAGGCAGACGGACGGT
GCGGGGTCTCCTCCTCTGTAATGGGGAGAAAAGGAGAGATG-3’for the transformation
of TR UL74 into ME and 5’-GGCTTGGTGGACTATGCTTAACGCTCTCATTCTCATGGGAG
CTTTTTGTATCGTATTACGACATTGCTGTTTCCAGAACTTTACTGCGACCACCACCAAA3’ and 5’CAGAATCAGCAGTGAGTACACGCAGGCAAGCCAAACCACAAGGCAGACGGACGGTGCGG
GGTCTCCTCCTCTGTCATGGGGAAAAAAGAGATGATAATGG for the transformation of
ME UL74 into TR.

The final heterologous UL74(gO) recombinants were verified by Sanger sequencing
of PCR products using the following primers: 5’GATGATTTTTACAAGGCACATTGTACATC-3’ and 5’-AACTAGGTCGTCTTGGAAGC-3’
for TRΔMEgO and 5’-CTCACAATGATTTTTACAATGCG-3’ and 5’AACTAGGTCGTCTTGGAAGC-3’ for MEΔTRgO.

Antibodies. Rabbit polyclonal antipeptide antibodies specific for TBgO and MEgO
were described previously [64]. Rabbit polyclonal antibodies specific for UL148
were described previously [136]. Rabbit polyclonal anti-peptide antibodies against
gH, gL, UL130, and UL131 were provided by David Johnson (Oregon Health and
Sciences University, Portland, OR, USA) [147]. Anti-UL128 monoclonal antibody
(MAb) 4B10 was provided by Tom Shenk (Princeton University, Princeton, NJ, USA)
[148]. MAb 28-4 directed against major capsid protein (MCP) and MAb 27-156
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directed against gB were provided by Bill Britt [149-150]. MAb CH160 against
cytomegalovirus (CMV) immediate early protein 1 (IE1) and IE2 was purchased
from Abcam (Cambridge, MA, USA).

Immunoblotting. HCMV-infected cells or cell-free virions were solubilized in 2%
SDS–20 mM Tris-buffered saline (TBS) (pH 6.8). Insoluble material was cleared by
centrifugation at 16,000 X g for 15min, and extracts were then boiled for 10 min. For
endoglycosidase H (endo H) or peptide N-glycosidaseF (PNGase F) treatment assays,
proteins were extracted in 1% Triton X-100 (TX100) plus 0.5% sodium
deoxycholate (DOC) in 20 mM Tris (pH 6.8) plus 100 mM NaCl (TBS-TX-DOC).
Extracts were clarified by centrifugation at 16,000 X g for 15 min and treated with
endo H or PNGase F according to the manufacturer’s instructions (New England
BioLabs). For reducing blots, dithiothreitol (DTT) was added to extracts to a final
concentration of 25 mM. After separation by SDS-PAGE, proteins were transferred
onto polyvinylidene difluoride (PVDF) membranes (Whatman) in a buffer
containing 10 mM NaHCO3 and 3mM Na2CO3 (pH 9.9) plus 10% methanol.
Transferred proteins were probed with MAbs or rabbit polyclonal antibodies, antirabbit or anti-mouse secondary antibodies conjugated with horseradish peroxidase
(Sigma-Aldrich), and Pierce ECL-Western blotting substrate (Thermo Fisher
Scientific). Chemiluminescence was detected using a Bio-Rad ChemiDoc MP imaging
system.
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Radiolabeling proteins. Cell cultures were incubated in labeling medium (Met-Cysfree DMEM plus 2% dialyzed FBS lacking methionine and cysteine) for 2 h at 37°C,
and [35S]methionine-cysteine was then added to 1 mCi/ml (EasyTag Express 35S
protein labeling mix; PerkinElmer). For chase experiments, label medium was
removed, and cultures were washed twice in DMEM plus 2% FBS supplemented
with a 10-fold excess of nonradioactive methionine and cysteine and then incubated
in this medium for the indicated times.

Immunoprecipitation. Cell extracts were harvested in TBS-TX-DOC supplemented
with 0.5% bovine serum albumin (BSA) and 1 mM phenylmethylsulfonyl fluoride
(PMSF), clarified by centrifugation at 16,000 X g for 15 min, adjusted to 2% SDS–30
mM DTT, and heated at 75°C for 15 min. The extracts were then diluted 35-fold with
TBS-TX-DOC supplemented with 0.5% BSA and 10 mM iodoacetamide, incubated on
ice for 15 min, and precleared with protein A-agarose beads (Invitrogen/Thermo
Fisher Scientific) for at 4°C for 2 h. Immunoprecipitation reactions were set up with
specific antibodies and protein A-agarose beads, and the mixtures were incubated
overnight at 4°C. Protein A-agarose beads were washed 3 times with TBS-TX-DOC,
and proteins were eluted with 2% SDS and 30 mM DTT in TBS at room temperature
(RT) for 15 min, followed by 75°C for 10 min. Eluted proteins were separated by
SDS-PAGE and analyzed with a Typhoon FLA-9500 imager (GE Healthcare Life
Sciences). Band densities were determined using ImageJ version 1.48 software.
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Quantitative PCR. Viral genomes were determined as described previously [133].
Briefly, cell-free HCMV stocks were treated with DNase I before extraction of viral
genomic DNA (PureLink viral RNA/DNA minikit; Life Technologies/Thermo Fisher
Scientific). Primers specific for sequences within UL83 were used with the MyiQ
real-time PCR detection system (Bio-Rad).

Superinfection of HCMV-infected cells with replication-defective adenovirus
vectors. The construction of Ad vectors expressing MEgO or GFP was described
previously [64]. Two days after HCMV infection, cells were superinfected with 20
PFU/cell of AdMEgO or AdGFP. Six days later, cell-free HCMV was collected from the
supernatant culture by centrifugation, and cells were harvested for immunoblotting.
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Chapter III. Polymorphisms in Human
Cytomeglaovirus gO exert epistatic influences
on cell-free and cell-to-cell spread, and
antibody neutralization on gH epitopes.

This chapter is modified version of the manuscript published
in Journal of Virology in March 2020; 10.1128/JVI.02051-19.
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Introduction
Recent application of state-of-the-art genomics approaches have begun to uncover a
greater and more complex genetic diversity of human cytomegalovirus (HCMV) than
had been appreciated [54, 55, 61, 139, 151-154]. Of the 165 canonical open reading
frames (ORFs) in the 235 kbp HCMV genome, 21 show particularly high nucleotide
diversity and are distributed throughout the otherwise highly conserved genome.
Links between specific genotypes and observed phenotypes are not well understood
and as a corollary outcome, the factors driving HCMV genetic diversity and
evolution remain speculative. This is further complicated by recombination between
genotypes that can shuffle the diverse loci into various combinations, and this may
result in epistasis where the phenotypic manifestation of a specific genotype of one
locus may be influenced by the specific genotypes of other loci. Thus, realizing the
full potential of modern genomics approaches towards the design of new
interventions, clinical assessments and predictions will require better mechanistic
understanding of the links between genotypes and phenotypes.

The UL74 ORF codes for glycoprotein (g) O and is one of the aforementioned highly
diverse loci of HCMV [19, 64, 155,156]. Most phylogenetic groupings indicate 8
genotypes or alleles of gO that differ in 10-30% of amino acids, predominately near
the N-terminus and in a short central region. These amino acid polymorphisms also
affect predicted N-linked glycan sites. The evolutionary origins of gO genotype
diversity are not understood. Studies that followed infected humans through
latency-reactivation cycles over several years demonstrated remarkable stability in
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UL74(gO) sequences, arguing against the idea of selective pressure from a
dynamically adapting host immune system as a driving force for gO diversity [59,
155]. The functional significance of gO diversity has only recently been addressed
and centers around its role as a subunit of the envelope glycoprotein complex
gH/gL/gO, which is involved in the initiation of infection into different cell types.

The general model for herpesvirus entry involves fusion between the virion
envelope and cell membranes mediated by the fusion protein gB and the regulatory
protein gH/gL [120, 122, 157]. The HCMV gH/gL can be unbound, or bound by gO or
the set of UL128-131 proteins [148, 158-160]. How these gH/gL complexes
participate to mediate infection is complicated and seems to depend on both the cell
type and whether the infection is by cell-free virus or direct cell-to-cell spread.
Efficient infection of all cultured cell types by cell-free HCMV is dependent on
gH/gL/gO, whereas infection of select cell types including epithelial and endothelial
cells additionally requires gH/gL/UL128-131 [125, 126, 130, 131, 133, 161].
Experiments involving HCMV mutants lacking either gO or UL128-131 suggested
that cell-to-cell spread in fibroblast cultures can be mediated by either gH/gL/gO or
gH/gL/UL128-131, whereas in endothelial and epithelial cells gH/gL/UL128-131 is
required, and it has remained unclear whether gH/gL/gO plays any role [126, 130,
132, 162]. While it is clear that gH/gL/gO can bind to the cell surface protein
PDGFRα via gO, and that gH/gL/UL128-131 can bind NRP2 and OR14I1 via UL128131, the specific function(s) of these receptor engagements is unclear, but may
include virion attachment, regulation of gB fusion activity, or activation of signal
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transduction pathways [31, 33, 163]. In the case of gH/gL/gO, binding to PDGFRα
activates signaling pathways, but these are not required for entry [31, 162, 134].
Stegmann et al. showed that binding of a gO null HCMV to fibroblasts and
endothelial cells was impaired, yet it is unclear whether this was due to lack of
PDGFRα engagement. [32]. Finally, Wu et al. reported coimmunoprecipitation of gB
with gH/gL/gO and PDGFRα, consistent with a role for the gH/gL/gO-PDGFRα
interaction in promoting gB fusion activity [134]. However, unbound gH/gL has
been shown to mediate cell-cell fusion and has also been found in stable complex
with gB in extracts of infected cells and extracellular virions [160, 164]. Thus,
although many of the key factors in HCMV entry and cell-to-cell spread have been
identified, their interplay in the various entry pathways is unclear. Moreover, the
influence of gO diversity remains a mystery.

The gH/gL complexes have been extensively studied as potential vaccine candidates
and neutralizing antibodies have been described that react with epitopes on gH/gL,
on UL128-131 and on gO [165–173]. Anti-UL128-131 antibodies neutralize with
high potency, but only on cell types for which gH/gL/UL128-131 is required for
entry; e.g., epithelial cells. In contrast, antibodies that react with epitopes on gH/gL
tend to neutralize virus on both fibroblasts and epithelial cells, but are far less
potent on fibroblasts, where only gH/gL/gO is needed for entry. One explanation for
these observations is that gO, with its extensive N-linked glycan decorations
presents more steric hindrance to antibodies accessing the underlying gH/gL
epitopes than do the UL128-131 proteins. Similar effects of glycans in shielding
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neutralizing epitopes have been described for HIV env, and for HCMV gN [174-175].
In support of this hypothesis for gO, Jiang et al. showed that focal spread of a gO null
HCMV in fibroblasts was more sensitive to anti-gH antibodies [176]. Recently, Cui et
al. described antibodies that reacted to a linear epitope on gH that exhibited strainselective neutralization that could not be explained by polymorphisms within the gH
epitope [177]. One possible explanation was that gO polymorphisms between the
strains imposed differential steric hindrances on these antibodies.

In this study we utilized a set of HCMV BAC-clones that represent the range of
phenotypic diversity in terms of gH/gL complexes. HCMV TB40/e (TB), TR and
Merlin (ME) differ dramatically in the amounts of gH/gL complexes in the virion
envelope and their infectivity on fibroblasts and epithelial cells. Extracellular virions
of TB and TR contain gH/gL predominately in the form of gH/gL/gO and are far
more infectious on both fibroblasts and epithelial cells than ME, which contains
overall lower amounts of gH/gL, predominately as gH/gL/UL128-131 [64, 133].
Each of these strains encodes a different representative of the 8 gO genotypes. In a
previous report, we demonstrated that variation in the UL74(gO) ORF was not
responsible for the observed differences between TR and ME. [178]. Rather, it was
shown that the amounts of gH/gL/gO in ME and TR virions were influenced by
different steady-state levels of gO present during progeny assembly. Kalser et al.
showed that replacing the gO of TB with that of Towne (TN) also did not affect the
levels of gH/gL complexes but may have enhanced the ability of TB to spread in
epithelial cell cultures [145]. Here, we have generated a set of heterologous gO
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recombinants to include 6 of the 8 genotypes in the genetic backgrounds of the
gH/gL/gO-rich strain TR and the gH/gL/UL128-131-rich ME to analyze how the
differences in gO sequence influence HCMV biology. The results demonstrate that gO
variation can have dramatic effects on cell-free entry, cell-to-cell spread and the
neutralization by anti-gH antibodies. In some cases opposite influences were
observed for a given gO genotype in the different backgrounds of TR and ME,
indicating epistasis with other genetic differences between these strains.

Results
Influences of gO polymorphisms on cell-free infectivity and tropism can be
dependent on the background strain. To examine the effects of gO polymorphism,
a set of recombinant viruses was constructed in which the endogenous UL74(gO)
ORFs of strain TR and ME were replaced with the UL74(gO) ORFs from 5 other
strains. BAC-cloned strains TR and ME were chosen as the backgrounds for these
studies since they represent gH/gL/gO-rich and gH/gL/UL128-131-rich strains
respectively [64, 133, 145]. Additionally, ME is restricted to a cell-to-cell mode of
spread in culture, whereas TR is capable of both cell-free and cell-to143 cell modes
of spread [126, 137, 179]. The intended changes to UL74(gO) in each recombinant
BAC were verified by sequencing the UL74 ORF and the flanking regions used for
BAC recombineering. However, it was recently reported that HCMV BAC-clones can
sustain various genetic deletions, and rearrangements, and mutations during rescue
in fibroblasts or epithelial cells, resulting in mixed genotype populations [141]. To
ensure that phenotypes characterized were the associated with the intended
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changes to UL74(gO) and not to other genetic changes sustained during BAC rescue
in fibroblasts, all analyses were performed on at least three independently BACrescued viral stocks.

As a basis for interpretation of the later biological comparisons among
recombinants, the levels of gH/gL complexes incorporated into the virion envelope
were analyzed by immunoblot as previously described [64, 133]. As in the previous
reports, TR contained predominantly gH/gL/gO, whereas ME contained mostly
gH/gL/UL128-131 (Fig 3.1, compare lane 1 in panels A and B). Propagation of ME
under conditions of UL131 transcriptional repression (denoted “Merlin-T” (MT) as
described [133, 137]), resulted in more gH/gL/gO and less gH/gL/UL128-131 (Fig
3.1C, lane 1). Some minor differences in the amounts of total gL, gH/gL/gO, and
gH/gL/UL128-131 were observed for some of the heterologous gO recombinants
relative to their parental strains. However, band density analyses showed that all
apparent differences were less than 3-fold and few reached statistical significance
when compared across multiple experiments, likely reflecting the limitations of
immunoblot as a precise quantitative method, as well as stock-to-stock variability in
glycoprotein composition (Table 3.1). Thus, consistent with our previous report,
differences between strains TR and ME in the abundance of gH/gL complexes are
predominately influenced by genetic background differences outside the UL74(gO)
ORF [178].
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Fig 3.1 Immunoblot analysis of gH/gL complexes in parental and heterologous gO
recombinant HCMV. Equal number of cell-free virions (as determined by qPCR) of HCMV TR
(A), ME (B), or MT (C) or the corresponding heterologous gO recombinants were separated
by reducing (upper two panels) or non-reducing (bottom panel) SDS-PAGE, and analyzed by
immunoblot with antibodies specific for major capsid protein (MCP) or gL. Blots shown are
representative of three independent experiments. Molecular mass markers(kDa) indicated
on each panel.

58

Table 3.1 Immunoblot band density analyses of parental and heterologous gO
recombinants.

While gH/gL/gO is clearly important for entry into both fibroblasts and epithelial
cells, the mechanisms are likely different since 1) fibroblasts clearly express the
gH/gL/gO receptor PDGFRα on their surface, whereas ARPE19 epithelial cells
express little or none of this protein [31, 162, 134, 180], and 2) entry into epithelial
cells requires gH/gL/UL128-131 in addition to gH/gL/gO [126, 161, 133]. Thus, it
was possible that gO polymorphisms would differentially affect replication in these
two cell types. To address this, fibroblast-to-epithelial tropism ratios were
determined for each parental strain and gO recombinant by inoculating cultures of
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fibroblasts and epithelial cells in parallel with equivalent amounts of cell-free virus
stocks. The number of infected cells in each culture was then determined by flow
cytometry using GFP expressed from the virus genome. Figure 3.2 shows the results
of these experiments as the fold preference for either cell type as a ratio, where “1”
indicates equal infection of both cell types. Stocks of the parental TR were
approximately 20-fold more infectious on fibroblasts than on epithelial cells (Fig
3.2A). Preference towards fibroblasts was greater for TR-recombinants expressing
MEgO(GT5), PHgO(GT2a), and TBgO(GT1c). In contrast, tropism ratios of TR
recombinants expressing ADgO(GT1a) and TNgO(GT4) were closer to 1, indicating
more equal infection of both cell types. Parental ME and all of the ME-based gO
recombinants had tropism ratios within the range of 6 in favor of fibroblasts to 3 in
favor of epithelial cells. Several of these viruses had variability between replicate
stocks where some had slight fibroblasts preference and others slight epithelial
preference (Fig 3.2B). Propagation of the ME-based viruses as MT greatly increased
the preference towards fibroblasts infection for all recombinants to a range of 30300 fold (Fig 3.2B). These results suggested that for the more gH/gL/gO-rich TR and
MT, gO polymorphisms may differentially influence the infection of fibroblasts and
epithelial cells, shifting the apparent relative tropism. However, such influences
were less pronounced for ME, consistent with the low abundance of gH/gL/gO
expressed by this virus.
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Fig 3.2 Relative fibroblast and epithelial cell tropism of parental and heterologous gO
recombinant HCMV. Cell-free stocks of HCMV TR (A), ME (B), or MT (C) or the
corresponding heterologous gO recombinants were serially diluted, and side-by-side
cultures of nHDF fibroblasts and ARPE19 epithelial cells were inoculated with equal
volumes of the dilutions. The number of infected cells was determined by flow cytometry
for GFP at 2 days post infection. Ratios greater than or equal to 1 of the number of each cell
type infected (fib/epi or epi/fib) are plotted for each of three independent sets of virus
stocks (black, open and striped bars).

It was not clear if the observed differences in tropism ratios were due to enhanced
infection of one cell type, reduced infection of the other cell type or a mixture of
both. To address this, specific infectivity (ratio of the number of virions to the
number of infectious units) was determined for each parental and recombinant on
both fibroblasts and epithelial cells. Multiple independent supernatant stocks of
each recombinant were analyzed by qPCR for encapsidated viral genomes and
infectious titers on both cell types were determined by flow cytometry
quantification of GFP-positive cells (Fig 3.3). For the TR-based viruses on
fibroblasts, MEgO(GT5), TBgO(GT1c), and TNgO(GT4) each resulted in moderately
enhanced infectivity (2 to 10-fold fewer genomes/IU) compared to the parental TR,
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and PHgO(GT2a) enhanced infectivity 30-fold. In contrast, ADgO(GT1a) dropped TR
infectivity below the detection limit of the flow cytometry-based assay (Fig 3.3A, top
panel). In our previous report, expression of MEgO in the TR background did not
appear to affect infectivity on fibroblasts [178]. This discrepancy was likely due to
the more sensitive flow cytometry readout used in the current studies as compared
to the plaque assay readout used previously. The infectivity of parental TR on
epithelial cells was about 20-fold lower than on fibroblasts (i.e., 20-fold higher
genomes/IU), but the relative effect of each heterologous gO was similar to that
observed on fibroblasts (Fig 3.3A, bottom panel). Thus, some of the gO changes had
dramatic effects on the infectivity of TR. Although these effects were manifest on
both cell types, they were more pronounced on fibroblasts and this explains the
observed differences in fibroblast preferences reported in Figure 3.2A.

62

Fig 3.3 Specific infectivity of parental and heterologous gO recombinant HCMV.
Extracellular HCMV stocks of HCMV TR (A), ME (B), or MT (C) or the corresponding
heterologous gO recombinants were quantified by qPCR for viral genomes, and infectious
units (IU) were determined by flow cytometry quantification of GFP-expressing nHDF
fibroblasts or ARPE-19 epithelial cells, 2 days post infection. Average genomes/IU of 3
independent set of virus stock are plotted, with error bars representing standard
deviations. Undetectable levels of infectivity indicated by ND (not determined). Asterisks (*)
denote p-values ≤ 0.05; one way ANOVA with Dunnett’s multiple comparisons test
comparing each recombinant to the parental in three independent experiments.

The infectivity of cell-free ME virions on both cell types was below the detection
limit of the flow cytometry-based assay and none of the changes to gO rescued
infectivity (Fig 3.3B). These results indicated that the cell-free virions of all of the
ME-based viruses were virtually non-infectious. When propagated as MT, infectivity
on both cell types was improved to levels comparable to TR and this was consistent
with our previous results (Fig 3.2C) [133, 178]. The only significant effect of gO
changes on MT was ADgO(GT1a), which reduced infectivity on both cell types,. Thus,
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as in the TR background, some changes to gO influenced infectivity of MT and this
was disproportionally manifest on fibroblasts compared to epithelial cells, but the
overall preference of all of the MT-based viruses was strongly in favor of fibroblasts.

It has been reported that gO-null HCMV are impaired for attachment to cells and
that soluble gH/gL/gO can block HCMV attachment [32, 181]. Thus, it was possible
that the observed changes to cell-free infectivity due to gO polymorphisms were
related to a role for gO in attachment. To test this hypothesis, each heterologous gO
recombinant was compared to the corresponding parental strain by applying cellfree virus stocks to fibroblast or epithelial cell cultures for approximately 20 min,
washing away the unbound virus and then counting the numbers of cell-associated
virions by immunofluorescence staining of the capsid-associated tegument protein
pp150 [32] (Fig 3.4 and Tables 3.2 and 3.3). Given the short incubation time, high
concentrations of input viruses were used to, and these inputs were equal for each
set of parental and heterologous gO recombinants within the constraints of the
stock concentrations. Higher inputs were required for ME to obtain detectable
numbers of bound virus, consistent with the low amounts of gH/gL/gO in these
virions. The average number of cell-associated virions per cell varied considerable
between experiments, likely reflecting the complex parameters expected to
influence virus attachment including stock concentration, cell state and variability in
the incubation time between experiments. In some cases, a given recombinant was
significantly different from parental in only one or two of the three experiments. It
was concluded that these specific gO isoforms did not affect binding or attachment
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of HCMV to cells. However, binding of TR_TNgO(GT4) and MT_ADgO(GT1a) were
each significantly lower than their respective parental viruses in all three
experiments on both fibroblasts and epithelial cells. While it was possible that the
reduced binding of MT_ADgO(GT1a) was due in part to the slightly lower amounts
of gH/gL/gO (Fig 3.1C and Table 3.1), the reduced binding of TR_TNgO(GT4) could
not be similarly explained since this virus had slightly more gH/gL/gO than the
parental TR (Fig 3.1A, Table 3.1). Moreover, reduced binding may help explain the
lower infectivity of MT_ADgO(GT1a)(Fig 3.3C), but the poor infectivity of
TR_ADgO(GT1a) could not be explained by poor binding, and the reduced binding of
TR_TNgO(GT4) did not result in reduction of infectivity (Fig 3.3A).
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Fig 3.4 Binding of parental and heterologous gO recombinant HCMV to fibroblasts.
Extracellular HCMV TR, ME, MT or the corresponding heterologous gO recombinants were
applied to nHDF for 20 min. Multiplicities (genomes/cell) were: TR-background viruses (1 x
104), ME-background viruses (5 x 104), MT- background viruses (1 x 104). After washing
away unbound virus, cultures were fixed and permeabilized with acetone and cellassociated virus particles were detected by immunofluorescence using antibodies specific
for the capsid-associated tegument protein, pp150. Cells were visualized by staining nuclei
with DAPI. (A)Representative fields of parental TR, ME, MT and heterologous gO
recombinants that consistently reduced binding in 3 independent experiments (Table 3.2).
(B) Mean particles per cell for representative experiments. Error bars represent the
standard deviation. Asterisks (*) denote p-values ≤ 0.05; one-way ANOVA with Dunnett’s
multiple comparisons test comparing each recombinant to the parental.

Table 3.2 Binding of parental and heterologous gO recombinant HCMV to fibroblasts.
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Table 3.3 Binding of parental and heterologous gO recombinant HCMV to epithelial cells.
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In sum, these analyses indicated that; 1) gO polymorphisms can influence the cellfree infectivity of HCMV. In some cases this was independent of any effects on
abundance of gH/gL/gO in the virion envelope or binding to cells (e.g. parental TR
and TR recombinants harboring MEgO(GT5), TBgO(GT1c), and ADgO(GT1a), had
dramatically different infectivity but comparable levels of gH/gL/gO and cell
binding). 2) The influence of some gO isoforms was dependent on the background
strain (e.g., PHgO(GT2a) enhanced TR infectivity but did not affect ME or MT and
TNgO(GT4) reduced binding of TR but had no effect on binding of ME or MT). 3)
While some heterologous gO recombinants had quantitatively different effects on
infectivity on fibroblast compared to epithelial cells, these did not change the
fundamental fibroblast preferences for either TR or MT. 4) Some of the heterologous
gOs did appear to change relative tropism of ME. However, the relevance of tropism
ratios for these viruses is questionable since the specific infectivity (genomes/IU)
analyses suggested that all ME-based recombinants were noninfectious on either
cell type. This was consistent with the highly cell-associated nature of ME [137,
179].

Polymorphisms in gO can differentially influence the mechanisms of cell-free
and cell-to-cell spread. The analyses described above focused on the cell-free
infectivity of HCMV, as indicative of a cell-free mode of spread. Cell-to-cell spread
mechanisms are likely important for HCMV, and while gH/gL complexes are clearly
important for cell-to-cell spread, the mechanisms in these processes are poorly
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characterized in comparison to cell-free infection. Strains TR and ME are well-suited
to compare the effects of gO polymorphisms on cell-free and cell-to-cell spread since
ME is mostly restricted to cell-to-cell due to the poor infectivity of cell-free virions
but can be allowed to also spread cell-free by propagation as MT, whereas TR can
spread by both cell-free and cell-to-cell mechanisms [126, 133, 137, 179].

To compare spread among heterologous gO recombinants, replicate cultures were
infected at low multiplicity, and at 12 dpi, foci morphology was documented by
fluorescence microscopy and the increased number of infected cells was determined
by flow cytometry. In fibroblasts cultures, parental TR and MT showed more diffuse
foci compared to the tight, localized focal pattern of parental ME, consistent with the
notion that TR and MT spread by both cell-free and cell-to-cell mechanisms whereas
ME was restricted to cell-to-cell spread (Fig 3.5A). Quantitatively, spread by
parental TR increased the numbers of infected cells 55-fold over 12 days, whereas
spread of TR_MEgO(GT5) and TR_PHgO(GT2a) were significantly reduced (Fig
3.5B). Spread of ME was slightly reduced by ADgO(GT1a), but was increased by
TNgO(GT4) (Fig 3.5C). Surprisingly, different effects on spread were observed for
MT where TBgO(GT1c) and TNgO(GT4) reduced spread, and ADgO(GT1a) increased
spread.
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Fig 3.5 Spread of parental and heterologous gO recombinant HCMV in fibroblast cultures.
Confluent monolayers of nHDF or HFFFTet (for “MT”) were infected with 0.003/cell of
HCMV TR (A, B), ME (A, C), MT (A, D) or the corresponding heterologous gO recombinants.
At 3 and 12 days post infection cultures were analyzed by fluorescence microscopy (A) or
by flow cytometry to quantitate the total number of infected (GFP+) cells (B-D). Plotted are
the average number of infected cells at day 12 per infected cell at day 3 in 3 independent
experiments. Error bars represent standard deviations. Asterisks (*) denote p-values ≤ 0.05;
one-way ANOVA with Dunnett’s multiple comparisons test comparing each recombinant to
the parental.
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A number of interesting incongruities were observed when comparing the cell-free
infectivity of some gO recombinants on fibroblasts to their respective spread
characteristics in fibroblasts; 1) Spread of TR_PHgO in fibroblasts was reduced
compared to the parental TR (Fig 3.5B), but the cell-free infectivity of this
recombinant was actually better (Fig 3.3A). Similarly, spread of both
MT_TBgO(GT1c) and MT_TNgO(GT4) were reduced in fibroblasts (Fig 3.5D), but
cell-free infectivity of both viruses was comparable to parental MT. 2) Conversely,
MT_ADgO(GT1a) spread better in fibroblasts (Fig 3.5D), but the cell-free infectivity
was substantially worse (Fig 3.3C). Since the efficiency of cell-free spread should
depend on both the specific infectivity and the quantities of progeny virus released
to the culture supernatants, it was possible that some of these incongruities
reflected offsetting differences in the quantity of cell-free virus released as
compared to their infectivity. To test this, progeny released from infected fibroblasts
into culture supernatants were quantified by qPCR. There were no significant
differences in the quantity of progeny released per cell for any of the TR or MEbased recombinants (Fig 3.6A, and B). Likewise, all of MT-based recombinants
released similar numbers of cell-free progeny exceptcfor MT_ADgO(GT1a), which
was reduced by approximately 4-fold (Fig 3.6C). Thus, the discrepancies between
efficiency of spread and cell-free infectivity could not be explained by offsetting
differences in the release of cell-free progeny. Rather, these results suggested that
gO polymorphisms can differentially influence the mechanisms of cell-free and cellto-cell spread in fibroblasts. The interpretation that gH/gL/gO can provide a specific
function for cell-to-cell spread was supported by the results that expression of
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ADgO(GT1a) and TNgO(GT4), respectively reduced and increased spread of the
strain ME, for which spread is almost exclusively cell-to-cell (Fig 3.5C).

Fig 3.6 Release of extracellular progeny by parental and heterologous gO recombinant
HCMV in fibroblast cultures. Cultures of nHDF or HFFFTet (for “MT”) were infected with 1
IU/cell of HCMV TR (A), ME (B), MT (C) or the corresponding heterologous gO recombinants
for 8 days. The number of infected cells was determined by flow cytometry and progeny
virus in culture supernatants was quantified by qPCR for viral genomes. The average
number of extracellular virions per mL in each of 3 independent experiments is plotted.
Error bars represent standard deviations. Asterisks (*) denote p-values ≤ 0.05; one-way
ANOVA with Dunnett’s multiple comparisons test comparing each recombinant to the
parental.

Spread was also analyzed in epithelial cell cultures. Here, foci of both TR and ME
remained tightly localized, suggesting predominantly cell-to-cell modes of spread
for both strains in this cell type (Fig 3.7A). The number of TR-infected cells
increased by only 5-6 fold over 12 days compared to approximately 25-fold for ME
(Fig 3.7B and C). The low efficiency of spread for TR in epithelial cells compared to
ME was documented previously and may relate to the low expression of
gH/gL/UL128-131 by TR compared to ME [126, 133, 142]. Expression of
TNgO(GT4) further reduced TR spread in epithelial cells (Fig 3.7B). In contrast, ME
spread was slightly reduced by TBgO(GT1c) and ADgO(GT1a), but nearly doubled by
73

TNgO(GT4). The observed increase in ME spread due to TNgO(GT4) was not
attributed to increased release of progeny to the culture supernatants in epithelial
cells (Fig 3.8). Note that spread of MT could not be addressed in epithelial cells,
since gH/gL/UL128-131 is clearly required for spread in these cells and its
repression would complicate analysis of the contribution of gO polymorphisms
[126]. Nevertheless, it is clear from these experiments that gO polymorphisms can
affect spread in epithelial cells and that this can depend on the background strain.
Specifically, TNgO(GT4) reduced TR spread but increased ME spread. This
suggested that although gH/gL/UL128-131 is required for efficient cell-to-cell
spread in epithelial cells, and may even be sufficient in the case of gO-null HCMV
[130, 132], gH/gL/gO may also contribute to the mechanism when present.
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Fig 3.7 Spread of parental and heterologous gO recombinant HCMV in epithelial cell
cultures. Confluent monolayers of ARPE19 cells were infected with 0.003 IU/cell of HCMV
TR (A, B), ME (A, C), or the corresponding heterologous gO recombinants. At 3 and 12 days
post infection cultures were analyzed by fluorescence microscopy (A) or by flow cytometry
to quantitate the total number of infected (GFP+) cells (B-D). Plotted are the average
number of infected cells at day 12 per 829 infected cell at day 3 in 3 independent
experiments. Error bars represent standard deviations Asterisks (*) denote p-values ≤ 0.05;
one-way ANOVA with Dunnett’s multiple comparisons test comparing each recombinant to
the parental.
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Fig 3.8 Release of extracellular progeny by parental and heterologous gO recombinant
HCMV ME in epithelial cell cultures. Cultures of ARPE19 epithelial cells were infected with
HFFF-tet-derived MT or corresponding heterologous gO recombinants at the highest
multiplicities possible given the specific infectivity of stocks reported in Fig 3.3
(approximately 0.0005 IU/cell). (Note: since APRE19 cells do not express TetR, after the
initial infection, MT replicates as ME). Cultures were then propagated by trypsinization and
reseeding of intact cells until the number of infected cells approached 90-100% by
microscopy inspection for GFP+ cells. After 8 more days, culture supernatants were then
analyzed by quantified by qPCR for viral genomes. The average number of extracellular
virions per mL in each of 3 independent experiments is plotted. Error bars represent
standard deviations. Asterisks (*) denote p-values ≤ 0.05; one-way ANOVA with Dunnett’s
multiple comparisons test comparing each recombinant to the parental.

Polymorphisms in gO can affect antibody neutralization on gH epitopes.
The extensive N-linked glycosylation of gO raised the possibility that gO could
present steric hindrance to the binding of antibodies to epitopes on gH/gL, as was
shown for HCMV gN and also HIV env [174, 175]. A corollary hypothesis was that
such effects might vary with the polymorphisms among gO isoforms. To address
this, neutralization experiments were conducted using two monoclonal anti-gH
antibodies; 14-4b, which recognizes a discontinuous epitope likely located near the
membrane proximal ectodomain of gH [165, 166] and AP86, which binds to a
continuous epitope near the N-terminus of gH [182]. Note that these experiments
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could only be performed with TR- and MT-based recombinants since the cell-free
progeny of ME-based viruses were found to be only marginally infectious (Fig 3.3B).

Parental TR and recombinants encoding MEgO(GT5), PHgO(GT2a) and TBgO(GT1c)
were completely neutralized on fibroblasts by mAb 14-4b, whereas TR_ADgO(GT1a)
and TR_TNgO(GT4) were significantly resistant (Fig 3.9A). There was more
variability among TR-based recombinants with mAb AP86 (Fig 3.9B). Here, parental
TR could only be neutralized to approximately 40% residual infection. TNgO(GT4)
rendered TR totally resistant to mAb AP86, and MEgO(GT5) also significantly
protected TR. In contrast, TR_TBgO(GT1c) and TR_ADgO(GT1a) were more sensitive
to mAb AP86. On epithelial cells neutralization by both antibodies was more potent
and complete than on fibroblasts, and there was less variability among gO
recombinants (Fig 3.9C, and D). This was consistent with the interpretation that
both 14-4b and AP86 could bind their epitopes on gH/gL/UL128-131 and that this
represented the majority of the observed neutralization on epithelial cells. However,
TR_TNgO(GT4) still displayed some reduced sensitivity to both antibodies,
suggesting that gH/gL/gO epitopes also contributed to neutralization on epithelial
cells.

MT-based recombinants were generally more sensitive to neutralization by 14-4b
than were TR-based viruses (compare 14-4b concentrations in Fig 3.9A and 3.10A).
Strikingly, whereas TNgO(GT4) conferred 14-4b resistance to TR, it did not in MT,
and instead ADgO(GT1a) provided resistance to 14-4b (Fig 3.10A). As was observed

77

for TR-based recombinants, 14-4b neutralization on epithelial cells was less affected
by gO polymorphisms (Fig 3.10B). Note that neutralization of MT-based
recombinants by AP86 could not be tested since MEgH harbors a polymorphism in
the linear AP86 epitope that precludes reactivity [182]. Together, these results
indicated that differences among gO genotypes can differentially affect antibody
neutralization on gH epitopes. Moreover, which gO genotype could protect against
which antibody depended on the background strain, suggesting the combined
effects of gO polymorphisms and gH/gL polymorphisms.
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Fig 3.9 Neutralization of parental HCMV TR and heterologous gO recombinant by anti-gH
antibodies. Genome equivalents of extracellular HCMV TR or the corresponding
heterologous gO recombinants were incubated with 0.025-250 mg/mL of anti-gH mAb 144b, or 0.01-100 mg/mL of anti-gH mAb AP86 and then plated on cultures of nHDF
fibroblasts (A and B) or ARPE19 epithelial cells (C and D). At 2 days post infection the
number of infected (GFP+) cells was determined by flow cytometry and plotted as the
percent of the no antibody control. (Left panels) Full titration curves shown are
representative of three independent experiments, each performed in triplicate. (Right
panels) Average percent of cells infected at the highest antibody concentrations in 3
independent experiments. Error bars represent standard deviations. Asterisks (*) denote p
values ≤ 0.05; one-way ANOVA with Dunnett’s multiple comparisons test comparing each
recombinant to the parental.
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Fig 3.10 Neutralization of parental HCMV MT and heterologous gO recombinant by anti-gH
antibodies. Genome equivalents of extracellular extracellular HCMV MT or the
corresponding heterologous gO recombinants were incubated with 0.025-250 mg/mL of
anti-gH mAb 14-4b and then plated on cultures of nHDF fibroblasts (A) or ARPE19
epithelial cells (B). At 2 days post infection the number of infected (GFP+) cells was
determined by flow cytometry and plotted as the percent of the no antibody control. (Left
panels) Full titration curves shown are representative of three independent experiments,
each performed in triplicate. (Right panels) Average percent of cells infected at the highest
antibody concentrations in 3 independent experiments. Error bars represent standard
deviations. Asterisks (*) denote p-values ≤ 0.05; one-way ANOVA with Dunnett’s multiple
comparisons test comparing each recombinant to the parental.

Discussion
Efficient cell-free infection of most, if not all cell types requires gH/gL/gO [130, 131,
133]. However, the details of the mechanisms, and the distinctions between the
roles of gH/gL/gO in cell-free and cell-to-cell spread remain to be clarified. While
there are naturally occurring amino acid polymorphisms in each subunit of
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gH/gL/gO, gO has the most dramatic variation, with 8 known genotypes (or alleles)
that differ between 10-30% of amino acids [64, 135, 155, 156]. All isoforms of gO
are predicted to have extensive N-linked glycan modifications and some of the
amino acid differences alter the predicted sites. In a previous report, we sought to
determine if gO polymorphisms were a factor influencing the different levels of
gH/gL/gO and gH/gL/UL128-131 in strains TR and ME. On the contrary, results
suggested that genetic differences outside the UL74(gO) ORF result in more rapid
degradation of gO in the ME-infected cells compared to TR, and this influences the
pool of gO available during progeny assembly [178]. Kalser et al. reported that gO
polymorphisms could differentially affect multi step replication kinetics in
fibroblasts and epithelial cells [145]. However, only TB was analyzed as the
background and distinctions between effects on cell-free and cell-to-cell spread
were unclear. In this report we constructed a matched set of heterologous gO
recombinants in the well-characterized, BAC-cloned strains TR and ME. Studies
included address aspects of cell-free and cell-to-cell spread, cell-type tropism and
neutralization by anti-gH antibodies. The results demonstrate that gO
polymorphisms can influence each of these parameters and the effects in some cases
were dependent on the genetic background, suggesting a number of possible
epistatic phenomena at play.

A commonly used measure to assess the tropism of HCMV strains, isolates and
recombinants is the ratio of infection between fibroblasts and other cell types,
including epithelial and endothelial cells [142, 145, 183, 184]. Expressions of this
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ratio have varied, but have generally involved a normalization of the epithelial or
endothelial infection to that of fibroblasts. Here we similarly determined the
infectious titer of each of the parental strains and heterologous gO recombinants on
both fibroblasts and epithelial cells and expressed ratios ≥1 (either
fibroblasts/epithelial or epithelial/fibroblasts) to indicate the fold cell type
preference or tropism of each virus (Fig 3.2). Both gH/gL/gO-rich viruses, TR and
MT, were strongly fibroblast-tropic and some heterologous gO isoforms enhanced
this preference, while others reduced it. In contrast, the gH/gL/UL128-131-rich
virus ME infected both cell type more equally (ratios closer to 1), and gO
polymorphisms had little effect. The limitation of any such measure of relative
tropism is that it does not determine whether the virus in question can efficiently
infect one cell type in particular, both or neither. Thus, any 2 viruses compared may
have the same fibroblast-to-epithelial cell infectivity ratio for completely different
reasons. To address this we also compared infectivity on both cell types using a
common comparison for all viruses, i.e., the number of virions in the stock as
determined by qPCR for DNAse-protected viral genomes in the cell-free virus stocks
(Fig 3.3). This analysis provided a measure of specific infectivity as the number of
genomes/IU, where the lower ratio indicates more efficient infection. Whether
higher genomes/IU values reflect the presence of greater numbers of bona fide
“defective” virions, or a lower probability or efficiency of each viable virion in the
stock to accomplish a detectable infection, and whether or how these two
possibilities are different is difficult to know for any type of virus. Nevertheless,
these analyses provided important insights to the tropism ratios reported. In
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general, the specific infectivity ratios of the gH/gL/gO-rich viruses TR and MT in
these experiments were in the range of 500-5000 genomes/IU on fibroblasts, but
these viruses were approximately 20-100 fold less infectious on epithelial cells,
explaining the strong fibroblast preference exhibited by these strains. The effect of
most heterologous gO isoforms was similar on both cell types, but often of larger
magnitude on fibroblasts. Thus, while all of the TR and MT-based gO recombinants
remained fibroblast tropic, the quantitatively different effects on the two cell types
influenced the magnitude of fibroblasts preference. Importantly, in no case did the
change of gO affect the fundamental fibroblast preference of either TR or MT. The
infectivity of the gH/gL/UL128-131-rich, ME-based viruses on both cell types was
undetectable in these assays. Thus, the near neutral fibroblast-to-epithelial tropism
ratios of the ME-based viruses seem to reflect an equal inability to infect either cell
type and any assertion of a “preference” for either cell type for extracellular ME
virions seems spurious.

Binding to PDGFRα through gO is clearly critical for infection of fibroblasts [31].
However, while gH/gL/gO is also important for infection of epithelial cells, the
literature is conflicted on the expression of PDGFRα and its importance for HCMV
infection in epithelial and endothelial cells [32, 133, 134,162, 163]. On either cell
type, possible mechanisms of gH/gL/gO include facilitating initial attachment to
cells, promoting gB mediated membrane fusion, and signaling though PDGFRα or
other receptors. While Wu et al. were able to coimmunoprecipitate gB with
gH/gL/gO and PDGFRα, Vanarsdall et al. showed that gH/gL without gO or UL128-
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131 can directly interact with gB and promote gB-fusion activity [134, 160, 164]. It
has also been shown that gH/gL/gO engagement of PDFGRα can elicit signaling
cascades, but that this is not required for infection [31, 134, 162]. In contrast, there
is evidence that gH/gL/gO can help facilitate initial virion attachment [32, 181]. In
our studies, TNgO(GT4) reduced binding of TR to both fibroblasts and epithelial
cells (Fig 3.4, Tables 3.2 and 3.3). However, the reduced binding of TR_TNgO(GT4)
did not result in reduced infection of either cell type, and there were other isoforms
of gO that either resulted in increased or decreased infectivity but were not
associated with any detectable alteration in binding. Thus, while gH/gL/gO may
contribute to initial binding, it is likely involved in other important mechanisms that
facilitate infection and these can be influenced by gO polymorphisms. For example,
it is possible that polymorphisms in gO can affect the nature and outcome of
PDGFRα engagement. In support of this hypothesis, Stegmann et al. showed that
mutation of conserved residues within the N-terminal variable domain of gO were
critical for PDGFRα binding [185]. Thus it is conceivable that the variable residues of
gO can alter the architecture of the interaction with PDGFRa. Alternatively, it may be
that there are other receptors on both cell types for gH/gL/gO and that gO
polymorphisms can affect those interactions. Also, the effects of several specific gO
isoforms observed in the TR-background were not observed in the ME or MTbackgrounds. Possible explanations for the apparent epistasis include not only the
differential contributions of polymorphisms in gH/gL, but also potential differences
between strains in other envelope glycoproteins, such as gB, or gM/gN may
influence the relative importance of gH/gL/gO for binding and infection.
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The mechanistic distinctions between cell-free and cell-to-cell spread of HCMV are
unclear. Spread of ME in both fibroblast, epithelial and endothelial cells is almost
exclusively cell-to-cell and this can be at least partially explained by the noninfectious nature of cell-free ME virions (Fig 3.3) [132, 137, 142, 179]. Laib Sampaio
et al. showed that inactivation of the UL74(gO)ORF in ME did not impair spread but
that a dual inactivation of both gO and UL128 completely abrogated spread [132].
This indicates that gH/gL/UL128-131 is sufficient for cell-to-cell spread in
fibroblasts or endothelial cells in the absence of gH/gL/gO, and it seems likely that
spread in epithelial cells might be similar in this respect. Our finding that various
heterologous gO isoforms can enhance or reduce spread of ME without affecting the
cell-free infectivity strongly suggest that while gH/gL/UL128-131 may be sufficient
for cell-to-cell spread, gH/gL/gO can modulate or mediate the process, if present in
sufficient amounts. In the context of MT, where expression of gH/gL/UL128-131 is
reduced to sub detectable levels [133, 137] the virus gained cell-free spread
capability, and yet some of the heterologous gO isoforms had opposite effects on
cell-free infectivity and spread (compare Fig 3.3C to 3.5D). Similar discorrelations
between cell-free infectivity and spread were observed for the naturally gH/gL/gOrich strain TR, albeit with different heterologous gO isoforms involved. That gO
polymorphisms can have opposite effects on cell-free and cell-to-cell spread
supports a hypothesis of mechanistic differences in how gH/gL/gO mediates the
two processes, and again these effects seem dependent on epistatic influences of the
different genetic backgrounds.
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Beyond the roles of gH/gL/gO in replication, the complex is likely a significant target
of neutralizing antibodies, and therefore a valid candidate for vaccine design.
Several groups have reported neutralizing antibodies that react with epitopes
contained on the gH/gL base of both gH/gL/UL128-131 and gH/gL/gO and others
that react to gO [165-173]. We found that changing the gO isoform can have
dramatic effects on the sensitivity to two anti-gH mAbs (Figs 3.9 and 3.10). In the TR
background on fibroblasts, both ADgO(GT1a) and TNgO(GT4) conferred significant
resistance to neutralization by 14-4b, which likely reacts to a discontinuous epitope
near the membrane proximal ectodomain of gH [165-166]. TNgO(GT4) also
conferred resistance to AP86, which reacts to a linear epitope near the N-terminus
of gH [182], whereas ADgO(GT1a) actually increased sensitivity of TR to AP86.
Neutralization by either antibody on epithelial cells was not significantly affected,
consistent with the notion that these antibodies can also neutralize by reacting to
gH/gL/UL128-131. Again, the strain background exerted considerable influence
over the effects of gO polymorphisms. For MT, it was ADgO(GT1a) that conferred
resistance to 14-4b, and the other isoforms had little or no effect. The observed
effects on neutralization on gH epitopes likely involve differences in how gO
variable regions or associated glycans fold onto gH/gL to exert differential steric
effects. Relatedly, the differential influence of gO isoforms in the two genetic
backgrounds suggests epistasis involving the additive effects of gO polymorphisms
with the more subtle gH polymorphisms, which together can differentially affect the
global conformation of the gH/gL/gO trimer.
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Previous analyses have suggested two groups of gH sequences defined by
polymorphisms at the N terminus, including the AP86 epitope [182, 186]. Of the
strains represented in this study, TB, TR and AD belong to the gH1 genotype and are
sensitive to AP86, whereas ME, TN and PH belong to gH2 genotype and are resistant
to AP86. The differential effects of gO recombinants reported here raise questions
about the combinations of gH and gO genotypes in HCMV circulating in human
populations. The recently published genome sequence datasets from clinical
specimens have been collected with short-read sequencing approaches, which allow
sensitive detection of the various gH and gO genotypes within samples, but not the
combinations of the two ORFs on individual genomes [54, 55, 139, 153]. To address,
this we analyzed 236 complete HCMV genome sequences of isolated strains and BAC
clones in the NCBI database (Fig 3.11). Approximately half the sequences were gH1
and the other half gH2. ADgO(GT1a) and TBgO(GT1c) genotypes were exclusively
linked to gH1, whereas MEgO(GT5) was exclusively linked to gH2. Other gO
genotypes were found mixed with both gH genotypes, but in most cases,
disproportionally with one of the gH genotypes. These analyses agreed with
Rasmussen et al who suggested a strong linkage between gH1 and gO1 genotypes
(note that their study predated the GT1a, 1, b, and 1c subdivisions) [135]. Thus, it
appears that gH and gO genotypes are non-randomly linked. This may be due in part
to the adjacent position of UL74(gO) and UL75(gH) on the HCMV genome and the
sequence diversity, together limiting the frequency of recombination, as suggested
by the high linkage-disequilibrium of this region reported by Lassalle et al [55]. In
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addition, our results may suggest linkage pressures based on functional
compatibility of gH and gO. However, it was worth noting that among the more
striking effects reported were the loss of cell-free infectivity and differential
sensitivity to neutralization by gH antibodies of TR_ADgO(GT1a). Together, with the
fact that TR and AD are of the same gH genotype, these results suggest epistatic
interplay of genetic variation of other loci with that of gH and gO.

Fig 3.11 Association of gH and gO genotypes in 236 complete HCMV genome sequences in
the NCBI database. Complete HCMV genome sequences were retrieved from the NCBI
nucleotide database using the keywords filter <human herpesvirus type 5 complete
genome>. The resulting set of 350 sequences was curated to remove duplicates or genomes
missing any of the UL74(gO) and UL75(gH) open reading frames, generating a working set
of 236 complete HCMV genomes, which were analyzed using MAFFT FFT-NS-I (v7.429)
phylogeny software. UL74(gO) and UL75(gH) sequences were assigned to their respective
genotype groups as defined previously; UL75(gH) genotypes 1 and 2 [182, 186]; UL74(gO)
genotypes 1a, 1b, 1c, 2a, 2b, 3, 4 and 5 [19, 156]. Shown is a phylogenetic tree of the 8 gO
genotypes with the frequency of pairing with either gH1 or gH2 . Asterisks (*) indicate gO
genotypes that were not analyzed in the experiments described herein.
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In conclusion, we have shown that naturally occurring polymorphisms in the HCMV
gO can have a dramatic influence on significant aspects of HCMV biology including,
cell-free and cell-to-cell spread, and neutralization by anti-gH antibodies. These
effects could not be explained by changes to the levels of gH/gL complexes in the
virion envelope, but rather point to changes in the mechanism(s) of gH/gL/gO in the
processes of cell-free and cell-to-cell spread. The associated epistasis with the global
genetic background highlights a particular challenge for intervention approaches
since humans can be superinfected with several combinations of HCMV genotypes
and recombination may occur frequently [54, 55, 61, 139, 151–154]. Moreover,
these observations could help explain the incomplete protection observed for the
natural antibody response against HCMV.

Materials and methods
Cell lines. Primary neonatal human dermal fibroblasts (nHDF; Thermo Fisher
Scientific), MRC-5 fibroblasts (ATCC CCL-171; American Type Culture Collection),
and HFFFtet cells (which express the tetracycline [Tet] repressor protein; provided
by Richard Stanton) [137] were grown in Dulbecco’s modified Eagle’s medium
(DMEM; Thermo Fisher Scientific) supplemented with 6% heat-inactivated fetal
bovine serum (FBS; Rocky Mountain Biologicals, Inc., Missoula, MT, USA) and 6%
bovine growth serum (BGS; Rocky Mountain Biologicals, Inc., Missoula, MT, USA)
and and with penicillin streptomycin, gentamycin and amphotericin B. Retinal
pigment epithelial cells (ARPE19) (American Type Culture Collection, Manassas, VA,
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USA) were grown in a 1:1 mixture of DMEM and Ham’s F-12 medium (DMEM:F12)(Gibco) and supplemented with 10% FBS and with penicillin streptomycin,
gentamycin and amphotericin B.

Human Cytomegalovirus (HCMV). All HCMV were derived from bacterial artificial
chromosome (BAC) clones. The BAC clone of TR was provided by Jay Nelson
(Oregon Health and Sciences University, Portland, OR, USA) [146]. The BAC clone of
Merlin (ME) (pAL1393), which carries tetracycline operator sequences in the
transcriptional promoter of UL130 and UL131, was provided by Richard Stanton
[137]. All BAC clones were modified to express green fluorescent protein (GFP) by
replacing the US11 ORF with the eGFP gene under the control of the murine CMV
major immediate early promoter. The constitutive expression of eGFP allows the
monitoring of HCMV infection early and was strain-independent. Infectious HCMV
was recovered by electroporation of BAC DNA into MRC-5 fibroblasts, as described
previously by Wille et al. [130] and then coculturing with nHDF or HFFFtet cells.
Cell-free HCMV stocks were produced by infecting HFF or HFFFtet cells at 2 PFU per
cell and harvesting culture supernatants at 8 to 10 days postinfection (when cells
were still visually intact). Harvested culture supernatants were clarified by
centrifugation at 1,000 X g for 15 min. Stock aliquots were stored at -80°C. Freezethaw cycles were avoided. Infectious unit (IU) were determined by infecting
replicate cultures of nHDF or ARPE19 with serial 10-fold dilutions and using flow
cytometry to count GFP positive cells at 48 hours post infection.
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Heterologous UL74(gO) recombinant HCMV. A modified, three step BAC En
Passant recombineering technique was performed [187-188]. In the first step, the
endogenous UL74 ORF from the start codon to the stop codon of both TR and ME
was replaced by a selectable marker. This necessary step was added to prevent
formation of chimeric UL74 gene by internal recombination of the UL74 BAC
sequence and the incoming heterologous UL74 ORF. A purified PCR product
containing the ampicillin resistance selectable marker (AmpR) cassette from the
pUC18 plasmid flanked by sequences homologous to 50 bp upstream and
downstream of the TR or ME UL74 ORF was electroporated into the bacteria,
recombination was induced and the recombinant-positive bacteria were selected on
medium containing ampicillin (50 μg/ml) and chloramphenicol (12.5 μg/ml). The
primers used to produce the TR- and ME-specific AmpR PCR bands are
For74TRamp, 5'CATGGGAGCTTTTTGTATCGTATTACGACATTGCTGTTTCCAGAACTTTAcgcggaaccccta
tttgtttatttttctaaatac, For74MEamp, 5'GATGGGAGCTTTTTGTATCGTATTACGACATTGCTGCTTCCAGAACTTTAcgcggaaccccta
tttgtttatttttctaaatac, and Rev74amp (used for both TR and ME PCR reactions), 5'CCAAACCACAAGGCAGACGGACGGTGCGGGGTCTCCTCCTCTGTCATGGGGttaccaatgctta
atcagtgaggcacc. The lower case nucleotides correspond to the AmpR gene from the
pUC18 plasmid, the upper case nucleotides to the TR and ME BAC sequences
immediately upstream and downstream of the UL74 ORF.
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In the second step, the AmpR cassette in the TR and ME first-step intermediate BACs
was replaced with the UL74(gO) sequence from the heterologous strain containing
the En Passant cassette [187-188]. Briefly, E. coli cultures were prepared for
recombination as described above for step 1 and electroporated with purified PCR
products containing the UL74 ORF from the TR or ME strain flanked by sequence
homologous to 50 bp upstream and downstream of the opposite strain. The UL74
ORF also contained an inserted En Passant cassette (an I-SceI site followed by a
kanamycin resistance gene surrounded by a 50-bp duplication of the UL74
nucleotides of the insertion site). Transformed E. coli cells were induced for
recombination and then selected for the swap of the UL74 En Passant sequence into
the BAC by growth on medium containing kanamycin (50 μg/ml) and
chloramphenicol (12.5 μg/ml). A PCR reaction analysis with primers located
upstream and downstream of UL74 was used to confirm the swap of the AmpR
cassette by the En Passant cassette/UL74 gene.

In the third step, several sequencing validated colonies of the second step were
subjected to the last step of the En Passant recombineering, that is, an induction of
both the I-SceI endonuclease and the recombinase [187-188]. The activity of these
enzymes lead to an intramolecular recombination in the UL74 sequence around the
En Passant cassette and thus the restoration of an uninterrupted, full length UL74
ORF. The final heterologous UL74(gO) recombinants were verified by Sanger
sequencing of PCR products using primers located upstream and downstream of the
UL74 gene.
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Antibodies. Monoclonal antibodies (MAbs) specific to HCMV major capsid protein
(MCP), pp150, and gH (14-4b and AP86) were provided by Bill Britt (University of
Alabama, Birmingham, AL) [165, 182, 189-190]. 14-4b and AP86 were purified by
FPLC and quantified by the University of Montana Integrated Structural Biology
Core Facility. Rabbit polyclonal sera against HCMV gL was described previously [64,
133].

Immunoblotting. HCMV cell-free virions were solubilized in 2% SDS–20 mM Trisbuffered saline (TBS) (pH 6.8). Insoluble material was cleared by centrifugation at
16,000 X g for 15min, and extracts were then boiled for 10 min. For reducing blots,
dithiothreitol (DTT) was added to extracts to a final concentration of 25 mM. After
separation by SDS-PAGE, proteins were transferred onto polyvinylidene difluoride
(PVDF) membranes (Whatman) in a buffer containing 10 mM NaHCO3 and 3mM
Na2CO3 (pH 9.9) plus 10% methanol. Transferred proteins were probed with MAbs
or rabbit polyclonal antibodies, anti-rabbit or anti-mouse secondary antibodies
conjugated with horseradish peroxidase (Sigma-Aldrich), and Pierce ECL-Western
blotting substrate (Thermo Fisher Scientific). Chemiluminescence was detected
using a Bio-Rad ChemiDoc MP imaging system. Band densities were quantified using
BioRad Image Lab v 5.1.

Quantitative PCR. Viral genomes were determined as described previously [133].
Briefly, cell-free HCMV stocks were treated with DNase I before extraction of viral
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genomic DNA (PureLink viral RNA/DNA minikit; Life Technologies/Thermo Fisher
Scientific). Primers specific for sequences within UL83 were used with the MyiQ
real-time PCR detection system (Bio-Rad).

Flow cytometry. Recombinant GFP-expressing HCMV-infected cells were washed
twice with PBS and lifted with trypsin. Trypsin was quenched with DMEM
containing 10% FBS and cells were collected at 500Xg for 5 min at RT. Cells were
fixed in PBS containing 2% paraformaldehyde for 10 min at RT, then washed and
resuspended in PBS. Samples were analyzed using an AttuneNxT flow cytometer.
Cells were identified using FSC-A and SSC-A, and single cells were gated using FSCW and FSC-H. BL-1 laser (488nm) was used to identify GFP+ cells, and only cells
with median GFP intensities 10-fold above background were considered positive.

Virus particle binding. nHDF or ARPE19 cells were seeded at density of 35,000
cells per cm2 on chamber slides (Nunc Lab Tek II). 2 days later, virus stocks were
diluted with media to equal numbers of virus particles based on genome
quantification by qPCR. Binding of virus particles to the cells was allowed for 20min
at 37°C. Then the inoculum was removed, and the cells were washed once with
medium to remove unbound virus before fixation and permeabilization with 80%
acetone for 5min. Bound virus particles were stained with an antibody against the
capsid-associated tegument protein pp150 [26] which allowed to detect enveloped
particles attached to the plasma membrane as well as internalized particles. For
visualization, a goat anti-mouse Alexa Fluor 488 (Invitrogen) secondary antibody
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was used. Unbound secondary antibody was washed off before the chambers were
removed and the cells were mounted with medium containing DAPI (Fluoroshield)
and sealed with a cover slide for later immunofluorescence analysis. Images were
taken with a Leica DM5500 at 630-fold magnification. For each sample 10 images
with 4 to 6 cells per image were taken and the number of cell nuclei as well as the
number of virus particles was determined using Image J Fiji software (v 1.0). Three
independent virus stocks were tested in 3 independent experiments.

Antibody neutralization assays. Equal numbers of nHDF-derived cell-free
parental viruses and heterologous gO recombinants were incubated with multiple
concentrations of anti-gH mAb 14-4b or AP86 for 1hr at RT then plated on nHDF or
ARPE19 for 4hrs at 37°C. Cells were then cultured in the appropriate growth
medium supplemented with 2% FBS. After 2 days, cells were detected from the dish
and fixed for flow cytometry analyses. Each antibody concentration was performed
in triplicate and 3 independent experiments were conducted.
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Chapter IV. Conclusion, discussion, and
future directions
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HCMV epidemiology, clinical pathology and genetic diversity
Human cytomegalovirus (HCMV) has high seroprevalence within human population.
Based on clinical observations, 50% of people acquire HCMV during childhood and
the rest contract this virus later on in their life [191]. Most human viruses attack
certain cell types, tissues, or organs, for example HIV specifically infects T-cells and
SARS-Cov-2 targets lungs [192-193]. In contrast, one unique characteristic of HCMV
is that it can spread throughout the body and cause clinical pathologies, including
gastroenteritis, encephalitis, retinitis, vasculopathies and so on [194].

With the development of high-throughput sequencing techniques in the past few
years, some geneticists and bioinformaticians have revealed a great degree of
genetic diversity of HCMV in clinical specimens [53-55,61,66,139,151,153,154].
Based on these studies, 21 out of 165 canonical genes have high diversity and they
are distributed in clusters across the viral genome. For each diverse gene, there are
2 to 14 different alleles detected among the clinical specimen samples. Since the
majority of the viral genome is conserved, recombination sites are widely spread
through the genome. The low linkage disequilibrium among the diverse loci
suggests the variable alleles may get shuffled among strains by recombination [55].
Theoretically, more than 1015 unique strains can be generated by possible
recombination events [Jean-Marc Lanchy, personnel communication]. Of the
approximately 240 complete genome sequences in the databases, each are unique in
their combination of these variable alleles. The inter-strain recombination suggests
that more than one individual HCMV virion may infect the same cell and actively
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replicate at the same time. Another important finding from the clinical specimen
sequencing study is that while there are many HCMV strains, which contain distinct
viral genomes, circulating in the peripheral blood, each body compartment may
have a limited number of strains.

UL74, which codes for glycoprotein O (gO), is one of the most diverse loci among the
variable genes described above. Based on the sequencing results using isolates
collected from congenitally infected newborns, transplant recipients, and HIV/AIDS
patients, 8 genotypes of gO are identified [135,156,195]. There are five major
genotypes (gO1, gO2, gO3, gO4 and gO5) and some of them are further divided into
minor subtypes (gO1a, gO1b, gO1c, gO2a, gO2b). The divergence of nucleotide
sequence between genotypes ranges between 3% to up to 55% [156]. The amino
acid sequence alignment of representative gO isoform from each genotype has
revealed regions of high diversity and regions of conservation (Fig 4.1A). The
majority of the diverse regions locate within the N-terminal 100 residues. A 20-22amino acid hydrophobic domain serving as the signal peptide that begins at the 14th
amino acid from the N-terminus [196]. After cleavage of signal peptide, the mature
gO has approximately 70 amino acids that are diverse at the N-terminus and the
residues from 270 to 340 also harbor notable diversity. There are 6 conserved
cysteine residues among gO isoforms, which locate at positions 31, 152, 160, 178,
229, and 354. Apart from cysteine 31 that is within the signal peptide, cysteine 354
is involved in forming disulfide bond with gH/gL and cysteine 178, 229 are
important for viral infectivity [64,124]. The amino acid sequence differences may
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lead to distinct characteristics and a good example is that the predicted N-link
glycosylation sites vary among the gO isoforms (Fig 4.1B).
A.

B.

Fig 4.1. (A) gO sequence alignment. Dark shading indicates conserved sequences. The
approximate positions of 6 conserved cysteine (C) are indicated. (Modified from [64]) (B)
Predicted N-link glycosylation sites on gO.

The role of gO in HCMV biology
gO does not have a transmembrane domain and it locates on the virion envelope
through forming a complex with glycoprotein H (gH) and glycoprotein L (gL). gH
and gL are found in all herpesviruses and they are part of the core membrane fusion
machinery for the virus family [120,122,197]. Within the gH/gL/gO complex, gH is
the one containing the transmembrane domain and anchoring the complex on the
lipid envelope, while gL forms disulfide bonds with both gH and gO. The gH/gL
heterodimer in the virion envelope can alternatively be found being bound by
UL128, UL130, and UL131, forming complex gH/gL/UL128-131 [159,161]. The
same gL cysteine 144 mediates binding to both gO and UL128, which suggests the
two gH/gL complexes are formed through competition [123].
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gH/gL/gO is critical for HCMV cell-free infection on all cell types, while
gH/gL/UL128-131 is additionally required for infecting certain cell types, such as
epithelial, endothelial, and leukocytes [125,126,130,131,132,133,161]. It has been
shown that platelet-derived growth factor receptor-α (PDGFR-α) on fibroblast cell is
a receptor for gH/gL/gO, and gO directly interacts with PDGFR-α [31,32]. The
interaction between gO and the receptor may contribute to viral infection by
enhancing viral attachment to the host cell and/or facilitating post-attachment
events, such as initiating signal transduction or triggering membrane fusion.

Compared to cell-free spread, the mechanisms of gH/gL complexes in cell-to-cell
spread are less understood. Previous study has shown that gO-null virus could still
spread cell-to-cell on fibroblasts and epithelial cells, which was most likely
facilitated by gH/gL/UL128-131. In contrast, the UL128-131-null virus could spread
cell-to-cell on fibroblasts but not on epithelial cells [179]. gO and UL128-131 double
knock out mutant completely abolished cell-to-cell spread, which suggests a
requirement for the participation of at least one gH/gL complex [132].

Based on studies using clinical human blood samples and an animal immunization
models, the epitopes on gH/gL are prime targets for neutralizing antibodies and
there is evidence suggesting that gO protects the virus from antibody neutralization
[116,166,168,176,198].

100

Despite the clear diversity at gO locus, there has been no evidence showing the
differences in gO sequence could cause functional variability. Since previous work
studied each role of gO within only one strain context, it was not clear whether the
observed gO functions could be affected by gO sequence diversity and whether
strain genetic background was involved in determining the phenotype outcome. In
this dissertation, I explored the significance of gO diversity in the following critical
aspects of HCMV biology in different strain genetic backgrounds:
Ø The assembly of gH/gL/gO and gH/gL/UL128-131
Ø The infectivity and tropism
Ø The cell-free vs. cell-to-cell spread
Ø The sensitivity to neutralizing antibody
Ø The epistatic effect of gO polymorphism

1.The assembly of gH/gL/gO and gH/gL/UL128-131
Previous studies have shown that strains containing distinct gO genotypes have
various amounts of gH/gL/gO and gH/gL/UL128-131 in their virion envelope [64].
Strain TB and TR have more gH/gL in total than strain ME. The gH/gL in strain TB
and TR are mostly in the gH/gL/gO form while ME is abundant in gH/gL/UL128131.

In this topic, I tested two factors that could contribute to the differential level of
gH/gL complexes among strains:
§

The expression level of gH/gL, gO and UL128, UL130, UL131
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§

The competition ability of gO sequences in gH/gL complexes formation

Strain TR was chosen as a representative for gH/gL/gO-rich virus and strain ME
represented for gH/gL/UL128-131 abundant virus. The results in Chapter 2 showed
that TR expressed similar amount of gH/gL as strain ME. However, the gH/gL in MEinfected cells were mostly associated with the ER, while TR’s gH/gL were predominantly residing in Golgi, indicating a higher chance of being assembled into
virion. This result was consistent with the observation that TR had more total
amount of gH/gL in the virion than ME. Much more UL128, 130, 131 were detected
in ME-infected cells than TR-infected cells, which directly correlated with ME’s high
gH/gL/UL128-131 phenotype. To study gO expression level, TR-ME gO open
reading frame swap mutants were generated to eliminate the caveat of using strainspecific antibodies to make a comparison. Both the immunoblot and quantitative
radiolabeling experiment results showed that ME produced significantly less
amounts of gO than TR. These results clearly demonstrated that the stoichiometry of
gO and UL128-131 expression plays an important role in gH/gL/gO and
gH/gL/UL128-131 assembly.

There was one previous study related to addressing the expression level of UL128131. It was found that strain TB, a gH/gL/gO-rich strain, possessed a G>T single
nucleotide polymorphism (SNP) compared to ME, which reduced the splicing of
mRNA encoding UL128, thus limited the assembly of gH/gL/UL128-131 [142].
However, this G>T SNP cannot fully explain strain TB’s low amount of
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gH/gL/UL128-131, since strain TR, which also contains small amounts of
gH/gL/UL128-131, has nucleotide G at the SNP position. The research on gO
expression was rather incomplete before this dissertation study. Based on the
quantitative radiolabeling experiment conducted in Chapter 2, ME infected cells
produced 27-fold less of gO than TR within 15min, which suggested the differences
in gO expression were due to some early stage events, such as UL74 (gO) mRNA
transcription, mRNA degradation, translation efficiency, or ER-associated rapid
degradation. Nguyen et al. provided evidence supporting the possibility of ERassociated degradation by showing that viral protein UL148 interacts with SEL-1, a
factor that plays a key role in ER-associated degradation. This study also showed
that gO was a substrate for ER-associated degradation and that UL148 could protect
gO from degradation [199]. UL148 has also been considered as a chaperon protein
in the ER facilitating gH/gL/gO formation [136], which correlates well with the
result in Chapter 2 that ME-infected cells contained less UL148 than TR.

The results in Chapter 2 further tested whether the low abundance of gO in MEinfected cells was the determinant factor for its low gH/gL/gO phenotype. The
overexpression of gO during ME replication did not increase the level of gH/gL/gO
in the virion unless the expression of UL128-131 was suppressed. Even then, the
change of gH/gL/gO level was marginal. These data taken together suggest that
there might be some other factors that affect the assembly of gH/gL complexes. One
potential candidate was discovered by Calo et al., who found that HCMV viral
glycoprotein UL116 competes with gL and forms a heterodimer with gH, and this
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gH/UL116 complex is located on infectious virion envelope [200]. It’s unclear
whether gL-gO or gL-UL128 competes with UL116 for binding to gH. If these
competitions do exist, which one is more competitive? This interesting question
could be followed up.

Swapping 6 gO isoforms into strain TR and ME had no impact on the level of gH/gL
complexes in the virion envelope. These results suggest that the strain genetic
background, loci outside of UL74 (gO), determines the level of gH/gL complexes in
the virion, and the diversity within the gO open reading frame does not affect gH/gL
complexes assembly.

New ideas for future work:
The mechanisms of differential expression levels of gO and UL128-131 between TR
and ME haven’t been fully characterized in this study and some potential future
work can be followed up on this topic.
1) Comprehensive RNA sequencing analysis on infected cells with multiple time
points may help to clear up whether UL74 of ME is transcribed with low efficiency
and/or whether ME’s UL74 mRNA has poor stability. Also, RNA sequencing data
would also provide information on understanding the mechanisms of UL128-131
expression differences between TR and ME.
2) Several connections around UL148: i) it favors gH/gL/gO formation, ii) it is
involved in ER-associated rapid degradation, and iii) ME expresses significantly less
UL148 than TR. Since polymorphisms exist in the UL148 locus between TR and ME,
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one specific direction for going forward is to generate UL148 swap mutants
between TR and ME, which may help to narrow down UL148’s function in
determining the gH/gL complexes assembly.
3) UL116 is a potential factor that influences gH/gL complex assembly. It is unclear
whether gL-gO or gL-UL128 can compete with UL116 for binding to gH inside of ER.
Adenovirus can be used as vector to deliver genes of interest into cells and
afterwards analyze the gH-associated complex by immunoprecipitation. Based on
the result from Chapter 3 that gO isoforms do not affect gH/gL composition in the
virion, it is hard to believe that the gO sequence has an impact on competition with
UL116. However, there are genetic polymorphisms at the UL116 locus. Between
strain TR and strain ME, there are 6 amino acid variations in UL116 sequence,
including TR>ME: Gly34 > Ser, Thr82 > Ala, Pro86 > Leu, Gly99 > Arg, Pro115 > Ser,
and Ala123 > Val. It is worth to look into whether these polymorphisms could
potentially change its structure or interaction with gH.

2. Infectivity and tropism
Strains TB, TR, and ME containing different gO genotypes have distinct cell-free
infectivity on different cell types [133]. The gH/gL/gO-rich strains TB and TR are
much more infectious than strain ME, which is abundant in gH/gL/UL128-131.
However, the level of gH/gL/gO in the virion cannot fully explain the infectivity
differences. In the case of MT, where the level of gH/gL/UL128-131 is reduced
during strain ME replication, the virion has slightly increased amounts of gH/gL/gO
and the infectivity is greatly improved. Despite much less of gH/gL/gO in the MT
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virion than strain TR, MT is more infectious than TR. From these previous analyses,
it seems that both the quantity and the quality of gH/gL/gO can impact the cell-free
infectivity. Since gO can directly interact with gH/gL/gO receptor PDGFR-α, it is
possible that gO isoforms have different characteristics in interacting with receptor
[31], which lead to various efficiencies in attachment, signal transduction, and
membrane fusion.

This dissertation tested the hypothesis that the amino acid sequences of gO directly
affect viral infectivity and tropism.

Since all the gO isoforms have no influence on the assembly of gH/gL complexes in
both strain TR and strain ME background. The gO swap mutant library was a
suitable reagent set for testing this hypothesis.

The cell-free infectivity analysis in Chapter 3 showed that several gO isoforms
significantly affected viral infectivity on both fibroblast and epithelial cells. For
example, MEgO, PHgO, and TNgO enhanced TR’s viral infectivity, while ADgO
dramatically dropped the infectivity down to below the detection limit of this flow
cytometry-based assay.

A common parameter used in the field for measuring the tropism is the ratio of
infection between fibroblast cells and other cell types, such as epithelial and
endothelial cells [142,145,184]. In this dissertation, I generated ratio of infectious
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titer between fibroblast cells and epithelial cells to look into the cell type preference
or tropism for each gO swap mutant virus. TR and MT, which contain much more
gH/gL/gO than gH/gL/UL128-131 in the virion envelope, were strongly fibroblast
tropic, and some gO isoforms enhanced this preference, while others reduced it.
However, in strain ME with abundant gH/gL/UL128-131, the tropism ratio was
close to equal. This result revealed the limitation of using the ratio of infection
between cell types as the parameter for evaluating viral tropism. The ratio
parameter overlooked the situation where viruses could not efficiently infect one
cell type in particular or both. Since none of the gO swap mutant in ME background
had detectable cell-free infectivity, it is a moot point to generate the tropism ratio.
The near neutral tropism ratio reflected these viruses’ equal incapability for
infecting fibroblast and epithelial cells. For MT gO swap mutants and majority of gO
swap mutants in TR background, they were capable of establishing cell-free
infection with reproducible viral infectivity. These viruses were approximately 20to 100-fold more infectious on fibroblast cells than on epithelial cells, thus showing
a preference for fibroblast cells. The impacts of gO isoforms in TR and MT were
similar on both cell types but exhibited a larger range on fibroblast cells. Thus,
although all of the TR- and MT-based gO swap mutants remained fibroblast cell
tropic, they were quantitatively different due to the various magnitude of fibroblast
cell preference.

Possible functions or mechanisms of gH/gL/gO in cell-free infection include
engaging receptor binding/attachment to cell, promoting gB-mediated fusion, and
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signaling through its receptor. Within the past few years, studies in the field have
investigated PDGFR-α as a receptor for gH/gL/gO on fibroblast cells. The cryo-EM
structure analysis indicated the interaction between gH/gL/gO and PDGFR- α was
through component gO [31]. However, it is unclear whether gH/gL/gO engages
binding to receptors on epithelial or endothelial cells. That soluble PDGFR-α preincubation with virus significantly prevented the infection on endothelial cells
suggested it is highly likely gH/gL/gO also has the function of receptor binding on
epithelial and endothelial cells [32]. Wu et al. showed that fusion protein gB could
be co-immunoprecipitated with gH/gL/gO and PDGFR-α, which supported the
hypothetical model in the field that gH/gL/gO interacts with gB to facilitate fusion
and this function may rely on receptor binding [134]. There was another study that
revealed that the gH/gL heterodimer could form a stable complex with the fusion
protein gB in the virion to perform fusion [160], however, distinguishing gB-gH/gLcomplex-mediated fusion compared to gH/gL/gO- or gH/gL/UL128-131-facilitated
fusion needs to be further investigated. The binding of gH/gL/gO does trigger cell
signaling through PDGFR-α. However, Wu et al. reported that only the extracellular
domain of PDGFR-α was critical for virus entry while the cell line with a PDGFR-α
intracellular tyrosine kinase domain knocked out had no influence on cell-free
infection [162].

For binding between gH/gL/gO and PDGFR-α, Stegmann et al. went one step further
and explored that the N-terminus of gO was important for binding to PDGFR-α.
Mutagenesis analysis uncovered the binding sites on gO were aa56-61 and aa117-
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121. These two binding sites are conserved within 3 out of 8 gO genotypes, which
are GT1a, GT1c and GT2 [185]. It remains to be explored whether other gO
genotypes bind to PDGFR-α through different binding sites or whether they utilize
other proteins on host cell surface as receptors. Since ADgO and PHgO contain the
conserved sites for binding to PDGFR-α, the previous findings cannot explain the
dramatic infectivity differences between TR_ADgO and TR_PHgO, where TR_PHgO
was 30-fold more infectious than TR and TR_ADgO’s infectivity was too poor to be
detected by the flow cytometry-based infectivity assay. It is possible that although
ADgO and PHgO contain the conserved binding sites, the co-folding between gH/gL
and gO are differentially altered by the sequence outside of the binding sites, which
leads to their distinct accessibility for binding to PDGFR-α and cell-free infectivity.
However, this possibility is framed under the assumption that PDGFR-α is the only
receptor for gH/gL/gO and the binding event between them is conserved. It is
possible that gH/gL/gO utilize multiple receptors on the host cell surface. A similar
phenomenon has been observed for herpes simplex virus-1 envelope glycoprotein
gD, which could bind to nectin-1, HVEM, or 3-O-sulfacted HS [201].

Considering that gH/gL/gO is involved in receptor binding, the study in Chapter 3
investigated whether the cell-free infectivity differences among gO recombinant
mutants were due to their various abilities for attachment. The results from the
attachment assay could not explain the distinct cell-free infectivity. For example,
ADgO in TR background dramatically dropped the infectivity down to below the
detection limit of the flow cytometry-based assay. However, TR_ADgO had no
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deficiency in binding to cells. In contrast, TR_TNgO was more infectious than TR,
while it had significantly less attachment than others on both fibroblast and
epithelial cells. This incongruity between cell-free infectivity and attachment
indicated that although gH/gL/gO-mediated attachment and fusion closely
coordinate, the efficiency of these two events are not completely linked together. It
is possible that gH/gL/gO with certain gO isoforms can bind to PDGFR-α with higher
affinity, however, the binding will not necessarily lead to fusion and vice versa.
Fewer virus particles attached to cells does not preclude the possibility that the gO
isoform could contribute to a hyper-fusogenic gH/gL/gO.

New ideas for future work:
The results of gO’s disproportional impacts on gH/gL/gO’s attachment and fusion
highlighted a big unknown in the field about how gH/gL/gO interacts with gB and
leads to fusion, and whether this interaction requires gH/gL/gO binding to its
receptor. It is also unclear whether gO is involved in this interaction interface
between gB and gH/gL/gO. It remains to be understood whether gH/gL/gO carrying
different gO genotypes have different binding affinity to PDGFR-α. In addition, the
viral attachment could be aided not only by the interaction between gH/gL/gO and
PDGFR-α, but also by other potential receptors for gH/gL/gO or other viral proteins
on the virion envelope. In order to explore these unknowns, some structure and
proteomics approaches would be fruitful.
1) In order to obtain information on the interaction between gB and gH/gL/gO, the
most direct approach is a structural study. Compared to crystallography, cryo-EM is
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a better approach for keeping all the glycan on the protein of interest. However,
since cryo-EM requires proteins being purified, it is going to be challenging to copurify gB and gH/gL/gO as a complex.
2) In regard to finding novel receptors for gH/gL/gO, the future work can start with
using soluble expressed and purified gH/gL/gO to bind to fibroblast or epithelial
cells, using immunoprecipitation and mass spectrometry to investigate gH/gL/gOassociated host cell proteins existed in the cytoplasmic membrane fraction. With the
development of high-resolution single-cell mass spectrometry technology, it will be
even possible to study the preference of gH/gL/gO for utilizing its receptors [202].
3) To investigate whether gH/gL/gO containing different gO isoforms have various
affinity for binding to PDGFR-α, surface plasmon resonance (SPR) can be utilized to
obtain the binding kinetics information.

3. The cell-free vs. cell-to-cell spread
HCMV cell-to-cell spread requires gH/gL complexes and either gH/gL/gO or
gH/gL/UL128-131 is sufficient for facilitating cell-to-cell spread on fibroblast cells,
while gH/gL/UL128-131 is indispensable for cell-to-cell spread on epithelial and
endothelial cells [132,179]. However, the roles of gH/gL complexes in cell-to-cell
spread have only been studied in cases of gO-null or UL128-131-null mutant. The
sufficiency of gH/gL/UL128-131 in cell-to-cell spread observed with gO-null mutant
could not rule out gH/gL/gO’s potential contribution in cell-to-cell spread. Schultz et
al. reported that strains were inherently different in their spread [205]. For
example, strain TB is highly dependent on cell-free mode of spread, while strain ME

111

spreads in a cell-to-cell manner. Since previous studies were based on different
single strain, it remains unclear whether gH/gL/gO and gH/gL/UL128-131 have
differential participations in spread for distinct strains.

To understand the mechanism of gH/gL/gO in facilitating cell-to-cell spread, the
following questions remained to be answered:
§

Does gH/gL/gO-mediated cell-to-cell spread also require receptor binding?

§

How does gO polymorphism affect the cell-to-cell mode of spread?

§

How does gH/gL/gO contribute to cell-to-cell spread with the presence of
gH/gL/UL128-131?

The results from spread analysis in Chapter 3 uncovered the influence of gO
polymorphism in cell-to-cell spread. On fibroblast cell, TR_PHgO had the best cellfree infectivity across all the mutants, however, the total spread rate of this mutant
(combination of cell-free and cell-to-cell spread) was the lowest, which indicated
gH/gL/PHgO was poorly efficient in cell-to-cell spread. Quite opposite, ADgO in TR
background was non-infectious for cell-free infection. However, TR_ADgO’s total
spread rate was similar to TR on fibroblast cells, which revealed that TR_ADgO had
potent ability in cell-to-cell spread and it could compensate the poor contribution
from cell-free spread. On epithelial cell, however, TR_ADgO had relatively slower
spread rate than TR, while TR_TNgO, which spread similar to TR on fibroblast cells,
had significantly reduced spread on epithelial cells, so the effects of gO isoforms on
viral spread were dependent on the cell type. Since cell-free viruses of ME gO

112

recombinants were non-infectious, the spread observed in Chapter 3 were
dominantly contributed by cell-to-cell mode. TBgO and ADgO significantly reduced
the spread of ME, while TNgO dramatically increased the spread on both fibroblast
and epithelial cells.

The indications from results mentioned above cleared up some confusion about
gH/gL/gO’s function in viral spread in the HCMV field. The differential impacts of gO
isoforms on two modes of spread enlightened that gH/gL/gO utilizes different
mechanisms in cell-free and cell-to-cell spread. It is possible that gH/gL/gO binds to
different receptors for facilitating the two modes of spread or the interaction
between gH/gL/gO and fusion protein gB is different at the cell-cell junction
compared to cell surface. The differential effects of gO polymorphisms on ME spread
in both fibroblast and epithelial cells uncovered that although gH/gL/UL128-131
was sufficient for facilitating cell-to-cell spread, gH/gL/gO could also contribute to
this process. In addition, the phenomenon of gO isoform’s various impacts between
cell types brought to light that gH/gL/gO participates in spread with different
fashion based on the cell type. One possibility that remains to be further studied is
the differential coordination/preference between gH/gL/gO and gH/gL/UL128-131
in facilitating membrane fusion in distinct cell types.

4. The sensitivity to neutralizing antibody
Previous studies reported that in clinical human samples and animal immunization
model, HCMV infection elicited antibodies mostly against gB, gH/gL, and UL128-131
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[166-170,198]. The common observation from these studies was that the antibodies
against gH/gL and UL128-131 in either human or animal serum neutralized HCMV
infection on epithelial or endothelial cells much more potently than on fibroblast
cells. There are many possible explanations for this phenomenon, such as antibodies
against UL128-131 can efficiently block the gH/gL/UL128-131 thus inhibiting the
entry on epithelial and endothelial cells. Another possibility is that the anti-gH/gL
antibodies elicited can’t bind to gH/gL/gO as easily as gH/gL/UL128-131, which
suggests a new potential function for gO as part of HCMV’s strategy for escaping the
host immune response. Several studies supported this possibility. Jiang et al.
showed that the focal growth of gO-null virus was much more sensitive to anti-gH
antibody than WT [176]. Cui et al. discovered that two HCMV strains, which
contained identical gH epitopes but distinct gO genotypes had different sensitivities
to anti-gH antibody [177]. All these observations taken together, generated one
hypothesis:
§

gO provides steric hindrance against anti-gH antibody binding, and this
protective effect varies among gO isoforms.

The gO recombinant library is a great tool set for addressing this hypothesis. The
neutralization assay in Chapter 3 tested the sensitivity of gO swap mutants to two
anti-gH monoclonal antibodies. Both TR_ADgO and TR_TNgO conferred significant
resistance to antibody 14-4b, which recognizes a conformational epitope located
near the transmembrane domain of gH. Anti-gH antibody AP86, which targets a
linear epitope near the N-terminus of gH. TR_TBgO and TR_ADgO, turned out to be
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more sensitive to AP86 than TR, while MEgO provided some resistance and
TR_TNgO showed 100% resistance to AP86 neutralization. In the MT context, ADgO
showed resistance to 14-4b, while others had similar sensitivity.

Taken together, these results indicated that gO could protect HCMV against anti-gH
antibody neutralization and that different gO isoforms might cover distinct epitopes
on gH. These findings may help to explain the great challenges in HCMV vaccine
development for HCMV where immunization with one or two attenuated strains, or
viral proteins failed to prevent natural acquisition of this virus during clinical trials
[203].

New ideas for future work:
In order to explore the mechanisms behind gO polymorphism’s differential impacts
on viral sensitivity to neutralizing antibody, three future studies are proposed here.
1) Characterization of binding between antibody and gO recombinant viruses.
For the recombinant virus that conferred resistance to antibody neutralization, if
the antibody does not bind or has weaker binding to the virus, it can simply explain
the resistance to neutralization is due to poor antibody binding. However, if the
antibody can bind to these recombinant viruses as well as others, it suggests that gO
may affect the folding of gH/gL during gH/gL/gO assembly. It is possible that gH
that is bound by the antibody yet still can interact with gB to trigger fusion.
2) Structural study of gH/gL/gO formed with various gO isoforms.
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Since gH, gL and gO are heavily glycosylated and the glycans may play important
roles in preventing antibody binding, solving structure of gH/gL/gO with glycan
information is critical. Compared to crystallography, which requires the glycans
being trimmed off from the proteins, cryo-EM is a better method for this study.
3) Characterization and comparison of the glycans on different gO isoforms by mass
spectrometry.
Wei et al. demonstrated that HIV utilized glycan on Env protein as an escaping
strategy for antibody neutralization [174]. Considering that gO is heavily
glycosylated and the predicted N-link glycan sites vary among gO isoforms, it is
possible that the glycan on gO can provide steric hindrance against the binding of
neutralizing antibody and gO isoforms containing different amino acid sequences
may carry distinct glycan compositions. However, the knowledge about gOassociated glycans are very limited currently and further study on this topic,
especially including different gO isoforms, will be very helpful for the
comprehensive understanding of gO.

5. The epistatic effect of gO polymorphism
Another set of interesting observations from my study was that some impacts of gO
isoforms were dependent on global strain genetic background.

The infectivity analyses in Chapter 3 showed that swapping ADgO into TR and MT
reduced the viral infectivity, however, PHgO and TNgO significantly enhanced the
viral infectivity in TR background on both fibroblast and epithelial cells but not in
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MT situation. Interestingly, the effects of certain gO isoforms on viral attachment
were also not identical in TR, ME and MT backgrounds, such as that TR_ADgO
attached to cell as well as TR, while MT_ADgO had significant reduced binding
compared to MT.

The characterization of viral spread on gO recombinants in TR and ME background
proved that the impacts of gO polymorphism in spread phenotype were also
dependent on strain genetic background. The isoform TNgO had no influence for
spread in TR background, but significantly enhanced the spread in ME, while PHgO
reduced the spread in TR background but not in ME.

Based on the neutralization analysis in Chapter 3, TNgO provided protection for TR
against antibody 14-4b neutralization, while TNgO did not protect MT. This
observation is more evidence indicating that the impacts of gO polymorphism are
subject to the global genetic background. One difference between TR and ME
background that may directly contribute to the epistatic effect in this neutralization
study is that the amino acid sequence 34-43 at the N-terminus of gH is not identical
between two strains. Based on this polymorphism at N-terminus, gH across
different strains of HCMV is assigned as gH1 genotype and gH2 genotype. Compared
to TR-gH (gH1), ME-gH (gH2) has a Proline missing and a substitution from
Histidine to Lysine [182]. Since Proline is often considered as a “helix breaker” and
Histidine has higher chance of being found around protein’s active or binding sites,
it is possible that the polymorphisms in gH can affect the structure of gH/gL/gO.
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To investigate the frequency of linkage between gH and gO genotypes, 236 complete
HCMV genome sequences were analyzed. The result in Chapter 3 showed that ADgO
and TBgO genotypes were exclusively linked to gH1, whereas MEgO was exclusively
linked to gH2. Other gO genotypes were found together with gH1 and gH2, however,
each gO genotype seemed to have a preference type between the two gH genotypes.
The preference of genotype combination between gO and gH may be due to the fact
that they locate right next to each other in the HCMV genome, with gO locating at
UL74 and gH at UL75, so the recombination chance is rare. It is also possible that
there are genes coded on the opposite strand of DNA, which restricts the
recombination between gH and gO locus. The sequencing analysis also confirmed
the high linkage disequilibrium between gH and gO locus [55]. The caveat for this
part of the study is that the genome sequences subjected to this analysis were
isolated strains and BAC clones, majority of which were extensively passaged on
fibroblast cells and went through selection pressure for adapting to propagation in
tissue culture. More advanced analyses based on the clinical specimen sequencing
data are required for better understanding of the linkage between gH genotypes and
gO genotypes.

In summary, the effects of gO isoforms were tested in different virus strain genetic
backgrounds in multiple aspects, including the infectivity, attachment, spread, and
sensitivity to neutralizing antibody. These findings stressed the important roles of
other variable loci apart from gO in determining the phenotypic features of HCMV
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and the observed influences of gO polymorphism were epistatic outcomes between
gO and other variable loci across the viral genome.

Perspectives
With more Next Generation Sequencing and bioinformatics data analyzed directly
on clinical samples, the connections and disconnections between laboratory
adapted strains and HCMV in clinical specimens started drawing more and more
attention.

The studies characterizing HCMV genomic sequence directly from clinical samples
revealed great complexity and diversity of HCMV [153-154]. There is substantial
strain diversity among individuals and this high diversity is likely due to high
frequency of mutations at nonfunctional genes and pervasive recombination
between strains. Within the host, multiple-strain infections are observed and up to 5
strains can be detected inside of one individual. The strains inside body
compartments of hosts are rather conserved and stable, suggesting the
compartments may place selection pressure on strain genotypes.

The major factor that causes disconnection between lab strains and clinical samples
is the method of isolating virus from clinical specimens. One piece of evidence from
studies in the field was that propagation of clinical isolates on fibroblasts could
rapidly select out mutations that heavily reduced or even abolished the expression
of UL128-131 proteins by inserting a stop codon within UL128 open reading frame
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[137,141]. The cell type for clinical sample propagation also plays critical role in the
process of isolation. The disrupting mutations in UL128 observed during fibroblast
propagation were not seen in epithelial cell passaging, which could be interpreted as
that gH/gL/UL128-131 has indispensible function on epithelial cell infection [140].
It has also been observed that 29 out of 30 clinical HCMV isolates that had the
potential to spread in endothelial cells lost that ability after long-term adaptation in
fibroblast cultures. In contrast, virus subjected to long-term adaptation on
endothelial cells retained both fibroblast tropism and endothelial tropism [204].
However, since it was unclear whether the isolates contained single or multiple
strains, the phenomenon described above might be due to mutation and/or strain
selection. Besides, there are mutations in genes occurred in regardless of culture cell
types, such as RL13, which encodes a highly glycosylated virion envelope protein
and has the potential to modulate tropism. Stanton et al. reported that a rapid and
reproducible frame-shift mutation occurred at RL13 locus when strain ME was
passaged on both fibroblast and epithelial cells and the mutation led to dramatic
repression on RL13 expression [137]. For other strains, such as TR, although the
same phenomenon was not observed, it is still under investigation whether RL13 in
these strains can be translated into protein and perform its function. In addition,
other sporadic mutations can be selected across HCMV genome during the
passaging of laboratory virus clones [141].

The result in Chapter 2 showed that overexpression of gO during ME replication
enhanced the infectivity by only 6-fold, while repression of UL128-131 enhanced

120

ME’s infectivity by 30- to 50-fold. These infectivity analyses suggested that the
selective pressure for losing UL128-131 was much stronger than gaining gO, thus it
is possible that the difference in gO expression between TR and ME reflects
sampling of the different genotypes exist in clinical specimens rather than
mutations raised during tissue culture propagation.

Although the question about how well the laboratory-adapted strains could
represent HCMV exist in nature remains unclear, multiple studies that conducted
Next Generation Sequencing analysis on clinical specimen samples concurred the
diversity of gO sequence in nature [53-55,66,153-154]. This dissertation focused on
studying the effects of gO sequence diversity as the connection between laboratory
research and HCMV exist in nature, and characterized the influences of gO
polymorphism on critical aspects of HCMV biology.

In conclusion, this dissertation research is fundamentally based on questions raised
from clinical sequencing studies and aimed for connecting the barrier between
laboratory study and clinical observations. The new findings include the mechanism
of gH/gL complex assembly and the dramatic influence of gO polymorphism on cellfree, cell-to-cell spread and neutralization by anti-gH antibodies. This study also
firstly elaborated that the impacts of gO polymorphism are subjected to epistatic
influences of the global genetic background. Although the study has inevitable
limitations in reflecting the features of virus found in clinic, hopefully these findings
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can provide more information for better understanding of HCMV pathology and
bring novel insights on vaccine design strategy.
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